date generated: 2021-02-09
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## x
## STK25 15.96852
## CCDC80 15.13535
## TLR4 -11.86789
## TFB2M -10.84115
## SH2B3 -10.74626
## MRGBP -10.27617
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2444 |
| num_genes_in_profile | 15982 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 7215 |
| num_profile_genes_not_in_sets | 8767 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2444 |
| num_genesets_excluded | 1144 |
| num_genesets_included | 1300 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Top N= 50 gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Interleukin-35 Signalling | 10 | 2.52e-04 | 0.668 | 3.28e-03 |
| Peptide chain elongation | 85 | 1.38e-24 | 0.642 | 1.79e-21 |
| Viral mRNA Translation | 85 | 4.65e-24 | 0.634 | 1.93e-21 |
| Selenocysteine synthesis | 88 | 3.64e-24 | 0.625 | 1.93e-21 |
| Eukaryotic Translation Elongation | 89 | 7.42e-24 | 0.617 | 1.93e-21 |
| Eukaryotic Translation Termination | 89 | 2.09e-22 | 0.597 | 3.89e-20 |
| Selenoamino acid metabolism | 101 | 6.14e-24 | 0.581 | 1.93e-21 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 97 | 9.13e-23 | 0.577 | 1.98e-20 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 91 | 1.49e-20 | 0.563 | 1.79e-18 |
| Interleukin-6 signaling | 11 | 1.28e-03 | 0.561 | 1.08e-02 |
| Formation of a pool of free 40S subunits | 97 | 1.39e-21 | 0.560 | 2.27e-19 |
| Activation of BAD and translocation to mitochondria | 12 | 8.12e-04 | -0.558 | 7.71e-03 |
| Signaling by Leptin | 10 | 2.69e-03 | 0.548 | 1.79e-02 |
| Chemokine receptors bind chemokines | 13 | 9.71e-04 | 0.528 | 8.89e-03 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 2.57e-03 | -0.525 | 1.77e-02 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 107 | 8.22e-21 | 0.523 | 1.19e-18 |
| RHO GTPases activate KTN1 | 10 | 4.53e-03 | -0.518 | 2.53e-02 |
| Degradation of cysteine and homocysteine | 11 | 2.96e-03 | -0.517 | 1.87e-02 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 108 | 1.51e-20 | 0.517 | 1.79e-18 |
| Synthesis of PIPs at the Golgi membrane | 15 | 5.86e-04 | -0.513 | 6.40e-03 |
| RHO GTPases activate IQGAPs | 10 | 5.31e-03 | -0.509 | 2.80e-02 |
| MAPK3 (ERK1) activation | 10 | 5.48e-03 | 0.507 | 2.86e-02 |
| Synthesis of PIPs at the early endosome membrane | 15 | 8.04e-04 | -0.500 | 7.69e-03 |
| tRNA processing in the mitochondrion | 24 | 3.01e-05 | -0.492 | 5.50e-04 |
| SRP-dependent cotranslational protein targeting to membrane | 108 | 2.11e-18 | 0.487 | 2.29e-16 |
| Cap-dependent Translation Initiation | 115 | 2.62e-18 | 0.471 | 2.44e-16 |
| Eukaryotic Translation Initiation | 115 | 2.62e-18 | 0.471 | 2.44e-16 |
| Early Phase of HIV Life Cycle | 12 | 4.77e-03 | -0.471 | 2.62e-02 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 4.98e-03 | -0.468 | 2.68e-02 |
| Interleukin-7 signaling | 17 | 8.95e-04 | 0.465 | 8.43e-03 |
| MicroRNA (miRNA) biogenesis | 23 | 1.20e-04 | -0.463 | 1.98e-03 |
| G beta:gamma signalling through CDC42 | 13 | 4.23e-03 | -0.458 | 2.44e-02 |
| G-protein beta:gamma signalling | 20 | 4.05e-04 | -0.457 | 4.96e-03 |
| Listeria monocytogenes entry into host cells | 19 | 6.52e-04 | -0.452 | 6.83e-03 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 13 | 4.84e-03 | -0.451 | 2.63e-02 |
| G beta:gamma signalling through PI3Kgamma | 15 | 2.78e-03 | -0.446 | 1.79e-02 |
| CRMPs in Sema3A signaling | 14 | 3.87e-03 | -0.446 | 2.32e-02 |
| Post-chaperonin tubulin folding pathway | 15 | 2.94e-03 | -0.444 | 1.86e-02 |
| Growth hormone receptor signaling | 19 | 9.89e-04 | 0.436 | 8.97e-03 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 111 | 2.87e-15 | 0.434 | 2.33e-13 |
| Nonsense-Mediated Decay (NMD) | 111 | 2.87e-15 | 0.434 | 2.33e-13 |
| Activation of G protein gated Potassium channels | 13 | 6.78e-03 | -0.434 | 3.27e-02 |
| G protein gated Potassium channels | 13 | 6.78e-03 | -0.434 | 3.27e-02 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 13 | 6.78e-03 | -0.434 | 3.27e-02 |
| Regulation of IFNA signaling | 11 | 1.31e-02 | 0.432 | 5.31e-02 |
| Notch-HLH transcription pathway | 25 | 2.12e-04 | -0.428 | 2.93e-03 |
| Establishment of Sister Chromatid Cohesion | 11 | 1.42e-02 | -0.427 | 5.56e-02 |
| Gluconeogenesis | 25 | 2.33e-04 | -0.425 | 3.19e-03 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 5.71e-05 | -0.425 | 1.02e-03 |
| Suppression of phagosomal maturation | 12 | 1.21e-02 | -0.418 | 5.13e-02 |
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Interleukin-35 Signalling | 10 | 2.52e-04 | 0.668000 | 3.28e-03 |
| Peptide chain elongation | 85 | 1.38e-24 | 0.642000 | 1.79e-21 |
| Viral mRNA Translation | 85 | 4.65e-24 | 0.634000 | 1.93e-21 |
| Selenocysteine synthesis | 88 | 3.64e-24 | 0.625000 | 1.93e-21 |
| Eukaryotic Translation Elongation | 89 | 7.42e-24 | 0.617000 | 1.93e-21 |
| Eukaryotic Translation Termination | 89 | 2.09e-22 | 0.597000 | 3.89e-20 |
| Selenoamino acid metabolism | 101 | 6.14e-24 | 0.581000 | 1.93e-21 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 97 | 9.13e-23 | 0.577000 | 1.98e-20 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 91 | 1.49e-20 | 0.563000 | 1.79e-18 |
| Interleukin-6 signaling | 11 | 1.28e-03 | 0.561000 | 1.08e-02 |
| Formation of a pool of free 40S subunits | 97 | 1.39e-21 | 0.560000 | 2.27e-19 |
| Activation of BAD and translocation to mitochondria | 12 | 8.12e-04 | -0.558000 | 7.71e-03 |
| Signaling by Leptin | 10 | 2.69e-03 | 0.548000 | 1.79e-02 |
| Chemokine receptors bind chemokines | 13 | 9.71e-04 | 0.528000 | 8.89e-03 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 2.57e-03 | -0.525000 | 1.77e-02 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 107 | 8.22e-21 | 0.523000 | 1.19e-18 |
| RHO GTPases activate KTN1 | 10 | 4.53e-03 | -0.518000 | 2.53e-02 |
| Degradation of cysteine and homocysteine | 11 | 2.96e-03 | -0.517000 | 1.87e-02 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 108 | 1.51e-20 | 0.517000 | 1.79e-18 |
| Synthesis of PIPs at the Golgi membrane | 15 | 5.86e-04 | -0.513000 | 6.40e-03 |
| RHO GTPases activate IQGAPs | 10 | 5.31e-03 | -0.509000 | 2.80e-02 |
| MAPK3 (ERK1) activation | 10 | 5.48e-03 | 0.507000 | 2.86e-02 |
| Synthesis of PIPs at the early endosome membrane | 15 | 8.04e-04 | -0.500000 | 7.69e-03 |
| tRNA processing in the mitochondrion | 24 | 3.01e-05 | -0.492000 | 5.50e-04 |
| SRP-dependent cotranslational protein targeting to membrane | 108 | 2.11e-18 | 0.487000 | 2.29e-16 |
| Cap-dependent Translation Initiation | 115 | 2.62e-18 | 0.471000 | 2.44e-16 |
| Eukaryotic Translation Initiation | 115 | 2.62e-18 | 0.471000 | 2.44e-16 |
| Early Phase of HIV Life Cycle | 12 | 4.77e-03 | -0.471000 | 2.62e-02 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 4.98e-03 | -0.468000 | 2.68e-02 |
| Interleukin-7 signaling | 17 | 8.95e-04 | 0.465000 | 8.43e-03 |
| MicroRNA (miRNA) biogenesis | 23 | 1.20e-04 | -0.463000 | 1.98e-03 |
| G beta:gamma signalling through CDC42 | 13 | 4.23e-03 | -0.458000 | 2.44e-02 |
| G-protein beta:gamma signalling | 20 | 4.05e-04 | -0.457000 | 4.96e-03 |
| Listeria monocytogenes entry into host cells | 19 | 6.52e-04 | -0.452000 | 6.83e-03 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 13 | 4.84e-03 | -0.451000 | 2.63e-02 |
| G beta:gamma signalling through PI3Kgamma | 15 | 2.78e-03 | -0.446000 | 1.79e-02 |
| CRMPs in Sema3A signaling | 14 | 3.87e-03 | -0.446000 | 2.32e-02 |
| Post-chaperonin tubulin folding pathway | 15 | 2.94e-03 | -0.444000 | 1.86e-02 |
| Growth hormone receptor signaling | 19 | 9.89e-04 | 0.436000 | 8.97e-03 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 111 | 2.87e-15 | 0.434000 | 2.33e-13 |
| Nonsense-Mediated Decay (NMD) | 111 | 2.87e-15 | 0.434000 | 2.33e-13 |
| Activation of G protein gated Potassium channels | 13 | 6.78e-03 | -0.434000 | 3.27e-02 |
| G protein gated Potassium channels | 13 | 6.78e-03 | -0.434000 | 3.27e-02 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 13 | 6.78e-03 | -0.434000 | 3.27e-02 |
| Regulation of IFNA signaling | 11 | 1.31e-02 | 0.432000 | 5.31e-02 |
| Notch-HLH transcription pathway | 25 | 2.12e-04 | -0.428000 | 2.93e-03 |
| Establishment of Sister Chromatid Cohesion | 11 | 1.42e-02 | -0.427000 | 5.56e-02 |
| Gluconeogenesis | 25 | 2.33e-04 | -0.425000 | 3.19e-03 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 5.71e-05 | -0.425000 | 1.02e-03 |
| Suppression of phagosomal maturation | 12 | 1.21e-02 | -0.418000 | 5.13e-02 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 15 | 5.20e-03 | -0.417000 | 2.75e-02 |
| RAS processing | 17 | 3.03e-03 | -0.415000 | 1.90e-02 |
| Spry regulation of FGF signaling | 16 | 4.24e-03 | -0.413000 | 2.44e-02 |
| Formation of the ternary complex, and subsequently, the 43S complex | 49 | 6.03e-07 | 0.412000 | 2.01e-05 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 15 | 7.51e-03 | -0.399000 | 3.50e-02 |
| Cytosolic iron-sulfur cluster assembly | 11 | 2.28e-02 | -0.397000 | 7.59e-02 |
| Negative regulation of FGFR3 signaling | 22 | 1.31e-03 | -0.396000 | 1.10e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 13 | 1.37e-02 | -0.395000 | 5.45e-02 |
| Triglyceride metabolism | 20 | 2.29e-03 | -0.394000 | 1.65e-02 |
| Basigin interactions | 18 | 3.90e-03 | -0.393000 | 2.32e-02 |
| RUNX3 regulates NOTCH signaling | 14 | 1.10e-02 | -0.392000 | 4.76e-02 |
| PKMTs methylate histone lysines | 40 | 1.76e-05 | -0.392000 | 3.64e-04 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 3.19e-02 | 0.392000 | 9.62e-02 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 22 | 1.50e-03 | -0.391000 | 1.22e-02 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 1.97e-02 | -0.389000 | 6.94e-02 |
| ERKs are inactivated | 13 | 1.57e-02 | -0.387000 | 5.82e-02 |
| Repression of WNT target genes | 12 | 2.09e-02 | -0.385000 | 7.22e-02 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 16 | 7.72e-03 | -0.385000 | 3.55e-02 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 16 | 7.72e-03 | -0.385000 | 3.55e-02 |
| Activation of BH3-only proteins | 26 | 7.48e-04 | -0.382000 | 7.39e-03 |
| rRNA processing in the mitochondrion | 26 | 7.61e-04 | -0.381000 | 7.39e-03 |
| Glyoxylate metabolism and glycine degradation | 20 | 3.18e-03 | -0.381000 | 1.98e-02 |
| EGFR downregulation | 27 | 6.19e-04 | -0.381000 | 6.57e-03 |
| RHO GTPases Activate WASPs and WAVEs | 32 | 2.05e-04 | -0.379000 | 2.87e-03 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 1.41e-02 | -0.379000 | 5.54e-02 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 1.50e-02 | -0.376000 | 5.65e-02 |
| Regulation of MECP2 expression and activity | 29 | 4.68e-04 | -0.375000 | 5.68e-03 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 19 | 4.64e-03 | -0.375000 | 2.57e-02 |
| Neurodegenerative Diseases | 19 | 4.64e-03 | -0.375000 | 2.57e-02 |
| Telomere C-strand synthesis initiation | 11 | 3.23e-02 | -0.373000 | 9.65e-02 |
| Thromboxane signalling through TP receptor | 15 | 1.26e-02 | -0.372000 | 5.21e-02 |
| Deactivation of the beta-catenin transactivating complex | 39 | 5.89e-05 | -0.372000 | 1.02e-03 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 20 | 4.06e-03 | -0.371000 | 2.39e-02 |
| Ribosomal scanning and start codon recognition | 56 | 1.95e-06 | 0.368000 | 5.77e-05 |
| Prostacyclin signalling through prostacyclin receptor | 11 | 3.54e-02 | -0.366000 | 1.02e-01 |
| Translation initiation complex formation | 56 | 2.18e-06 | 0.366000 | 6.28e-05 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 2.88e-02 | 0.364000 | 8.94e-02 |
| Negative regulation of FGFR4 signaling | 21 | 3.86e-03 | -0.364000 | 2.32e-02 |
| PRC2 methylates histones and DNA | 13 | 2.31e-02 | -0.364000 | 7.67e-02 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.48e-02 | -0.364000 | 5.60e-02 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.48e-02 | -0.364000 | 5.60e-02 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.48e-02 | -0.364000 | 5.60e-02 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 1.48e-02 | -0.364000 | 5.60e-02 |
| Signaling by GSK3beta mutants | 15 | 1.48e-02 | -0.364000 | 5.60e-02 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.48e-02 | -0.364000 | 5.60e-02 |
| SHC-mediated cascade:FGFR3 | 10 | 4.67e-02 | -0.363000 | 1.21e-01 |
| Ephrin signaling | 19 | 6.40e-03 | -0.361000 | 3.20e-02 |
| Diseases of mitotic cell cycle | 36 | 1.80e-04 | -0.361000 | 2.67e-03 |
| Thrombin signalling through proteinase activated receptors (PARs) | 21 | 4.32e-03 | -0.360000 | 2.45e-02 |
| Pausing and recovery of Tat-mediated HIV elongation | 25 | 1.91e-03 | -0.359000 | 1.43e-02 |
| Tat-mediated HIV elongation arrest and recovery | 25 | 1.91e-03 | -0.359000 | 1.43e-02 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 21 | 4.44e-03 | -0.359000 | 2.50e-02 |
| Collagen biosynthesis and modifying enzymes | 50 | 1.18e-05 | 0.358000 | 2.48e-04 |
| ERBB2 Regulates Cell Motility | 10 | 5.02e-02 | -0.358000 | 1.28e-01 |
| Scavenging by Class A Receptors | 10 | 5.07e-02 | 0.357000 | 1.29e-01 |
| MET activates RAP1 and RAC1 | 10 | 5.12e-02 | -0.356000 | 1.30e-01 |
| Mismatch Repair | 15 | 1.79e-02 | -0.353000 | 6.48e-02 |
| SUMOylation of transcription cofactors | 40 | 1.13e-04 | -0.353000 | 1.89e-03 |
| APC truncation mutants have impaired AXIN binding | 14 | 2.26e-02 | -0.352000 | 7.55e-02 |
| AXIN missense mutants destabilize the destruction complex | 14 | 2.26e-02 | -0.352000 | 7.55e-02 |
| Signaling by AMER1 mutants | 14 | 2.26e-02 | -0.352000 | 7.55e-02 |
| Signaling by APC mutants | 14 | 2.26e-02 | -0.352000 | 7.55e-02 |
| Signaling by AXIN mutants | 14 | 2.26e-02 | -0.352000 | 7.55e-02 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 2.26e-02 | -0.352000 | 7.55e-02 |
| HIV elongation arrest and recovery | 27 | 1.59e-03 | -0.351000 | 1.28e-02 |
| Pausing and recovery of HIV elongation | 27 | 1.59e-03 | -0.351000 | 1.28e-02 |
| Sema3A PAK dependent Axon repulsion | 15 | 1.87e-02 | -0.351000 | 6.68e-02 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 20 | 6.70e-03 | -0.350000 | 3.27e-02 |
| Interleukin-20 family signaling | 15 | 1.91e-02 | 0.350000 | 6.79e-02 |
| G beta:gamma signalling through BTK | 10 | 5.59e-02 | -0.349000 | 1.39e-01 |
| Collagen chain trimerization | 29 | 1.18e-03 | 0.348000 | 1.03e-02 |
| Inhibition of DNA recombination at telomere | 19 | 8.91e-03 | -0.347000 | 4.00e-02 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 35 | 3.94e-04 | -0.346000 | 4.88e-03 |
| Pre-NOTCH Transcription and Translation | 33 | 5.90e-04 | -0.346000 | 6.40e-03 |
| Negative regulation of MET activity | 20 | 7.54e-03 | -0.345000 | 3.50e-02 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 2.55e-02 | -0.345000 | 8.16e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 57 | 6.73e-06 | 0.345000 | 1.56e-04 |
| Removal of the Flap Intermediate | 14 | 2.58e-02 | -0.344000 | 8.20e-02 |
| SUMOylation of DNA methylation proteins | 14 | 2.58e-02 | -0.344000 | 8.20e-02 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 3.25e-02 | 0.342000 | 9.66e-02 |
| Defective EXT2 causes exostoses 2 | 13 | 3.25e-02 | 0.342000 | 9.66e-02 |
| Citric acid cycle (TCA cycle) | 21 | 6.61e-03 | -0.342000 | 3.24e-02 |
| Formation of tubulin folding intermediates by CCT/TriC | 18 | 1.23e-02 | -0.341000 | 5.19e-02 |
| Regulation of expression of SLITs and ROBOs | 158 | 1.62e-13 | 0.340000 | 1.17e-11 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 2.22e-03 | -0.340000 | 1.62e-02 |
| G alpha (12/13) signalling events | 59 | 6.92e-06 | -0.339000 | 1.58e-04 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 18 | 1.31e-02 | -0.338000 | 5.31e-02 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 2.39e-02 | -0.337000 | 7.81e-02 |
| Processive synthesis on the lagging strand | 15 | 2.39e-02 | -0.337000 | 7.81e-02 |
| Gap junction degradation | 10 | 6.55e-02 | -0.336000 | 1.52e-01 |
| Interleukin-10 signaling | 25 | 3.62e-03 | 0.336000 | 2.22e-02 |
| RHO GTPases activate PKNs | 28 | 2.15e-03 | -0.335000 | 1.59e-02 |
| ADP signalling through P2Y purinoceptor 12 | 13 | 3.68e-02 | -0.335000 | 1.04e-01 |
| Nuclear Envelope (NE) Reassembly | 66 | 2.88e-06 | -0.333000 | 7.97e-05 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 24 | 4.79e-03 | -0.333000 | 2.62e-02 |
| Sulfur amino acid metabolism | 21 | 8.67e-03 | -0.331000 | 3.90e-02 |
| Assembly of collagen fibrils and other multimeric structures | 45 | 1.31e-04 | 0.330000 | 2.12e-03 |
| Regulation of beta-cell development | 22 | 7.61e-03 | -0.329000 | 3.52e-02 |
| RA biosynthesis pathway | 13 | 4.07e-02 | 0.328000 | 1.12e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 6.02e-02 | -0.327000 | 1.46e-01 |
| Signaling by FGFR1 | 38 | 4.91e-04 | -0.327000 | 5.75e-03 |
| Uptake and function of anthrax toxins | 11 | 6.10e-02 | -0.326000 | 1.47e-01 |
| Sema4D in semaphorin signaling | 22 | 8.11e-03 | -0.326000 | 3.70e-02 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 7.43e-02 | -0.326000 | 1.65e-01 |
| Collagen formation | 71 | 2.22e-06 | 0.325000 | 6.28e-05 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 11 | 6.22e-02 | -0.325000 | 1.47e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 7.21e-03 | -0.324000 | 3.42e-02 |
| Cell-extracellular matrix interactions | 15 | 3.00e-02 | -0.324000 | 9.27e-02 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 1.26e-02 | -0.322000 | 5.21e-02 |
| HS-GAG biosynthesis | 24 | 6.39e-03 | 0.322000 | 3.20e-02 |
| Trafficking and processing of endosomal TLR | 10 | 7.87e-02 | 0.321000 | 1.73e-01 |
| Interferon alpha/beta signaling | 45 | 1.96e-04 | 0.321000 | 2.77e-03 |
| SUMOylation of transcription factors | 18 | 1.86e-02 | -0.320000 | 6.68e-02 |
| ROS and RNS production in phagocytes | 21 | 1.12e-02 | -0.320000 | 4.79e-02 |
| Complex I biogenesis | 52 | 7.46e-05 | -0.318000 | 1.28e-03 |
| Influenza Viral RNA Transcription and Replication | 130 | 4.21e-10 | 0.317000 | 2.38e-08 |
| Vpr-mediated nuclear import of PICs | 33 | 1.84e-03 | -0.313000 | 1.43e-02 |
| Sema4D induced cell migration and growth-cone collapse | 18 | 2.14e-02 | -0.313000 | 7.36e-02 |
| Negative regulation of FGFR2 signaling | 22 | 1.13e-02 | -0.312000 | 4.81e-02 |
| Cohesin Loading onto Chromatin | 10 | 8.87e-02 | -0.311000 | 1.86e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 10 | 8.94e-02 | -0.310000 | 1.87e-01 |
| SHC1 events in EGFR signaling | 10 | 9.05e-02 | -0.309000 | 1.89e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 1.43e-02 | -0.309000 | 5.58e-02 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 1.43e-02 | -0.309000 | 5.58e-02 |
| Receptor-type tyrosine-protein phosphatases | 18 | 2.43e-02 | 0.307000 | 7.88e-02 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 35 | 1.71e-03 | -0.306000 | 1.34e-02 |
| Signaling by RAS mutants | 35 | 1.71e-03 | -0.306000 | 1.34e-02 |
| Signaling by moderate kinase activity BRAF mutants | 35 | 1.71e-03 | -0.306000 | 1.34e-02 |
| Signaling downstream of RAS mutants | 35 | 1.71e-03 | -0.306000 | 1.34e-02 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 23 | 1.10e-02 | -0.306000 | 4.76e-02 |
| Signaling by WNT in cancer | 32 | 2.74e-03 | -0.306000 | 1.79e-02 |
| Activation of kainate receptors upon glutamate binding | 16 | 3.43e-02 | -0.306000 | 1.00e-01 |
| Pre-NOTCH Processing in Golgi | 14 | 4.79e-02 | -0.305000 | 1.23e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 42 | 6.21e-04 | -0.305000 | 6.57e-03 |
| Regulation of actin dynamics for phagocytic cup formation | 50 | 1.89e-04 | -0.305000 | 2.77e-03 |
| Voltage gated Potassium channels | 18 | 2.61e-02 | 0.303000 | 8.25e-02 |
| Negative regulation of FGFR1 signaling | 24 | 1.06e-02 | -0.301000 | 4.61e-02 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 175 | 7.35e-12 | 0.300000 | 4.78e-10 |
| Triglyceride catabolism | 14 | 5.26e-02 | -0.299000 | 1.32e-01 |
| G-protein activation | 14 | 5.27e-02 | -0.299000 | 1.32e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 44 | 6.04e-04 | -0.299000 | 6.49e-03 |
| EPHB-mediated forward signaling | 32 | 3.45e-03 | -0.299000 | 2.12e-02 |
| CASP8 activity is inhibited | 10 | 1.02e-01 | 0.299000 | 2.06e-01 |
| Dimerization of procaspase-8 | 10 | 1.02e-01 | 0.299000 | 2.06e-01 |
| Regulation by c-FLIP | 10 | 1.02e-01 | 0.299000 | 2.06e-01 |
| Olfactory Signaling Pathway | 10 | 1.03e-01 | -0.298000 | 2.07e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus | 31 | 4.19e-03 | -0.297000 | 2.43e-02 |
| Interactions of Vpr with host cellular proteins | 36 | 2.05e-03 | -0.297000 | 1.53e-02 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 35 | 2.42e-03 | -0.296000 | 1.69e-02 |
| HIV Transcription Elongation | 35 | 2.42e-03 | -0.296000 | 1.69e-02 |
| Tat-mediated elongation of the HIV-1 transcript | 35 | 2.42e-03 | -0.296000 | 1.69e-02 |
| NOTCH1 Intracellular Domain Regulates Transcription | 46 | 5.18e-04 | -0.296000 | 5.96e-03 |
| Binding and Uptake of Ligands by Scavenger Receptors | 17 | 3.47e-02 | 0.296000 | 1.01e-01 |
| FRS-mediated FGFR3 signaling | 12 | 7.66e-02 | -0.295000 | 1.69e-01 |
| SUMOylation of ubiquitinylation proteins | 37 | 1.90e-03 | -0.295000 | 1.43e-02 |
| Glucagon-type ligand receptors | 17 | 3.53e-02 | -0.295000 | 1.02e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 13 | 6.57e-02 | 0.295000 | 1.52e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer | 24 | 1.24e-02 | -0.295000 | 5.21e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 37 | 1.96e-03 | -0.294000 | 1.47e-02 |
| Signaling by ERBB2 TMD/JMD mutants | 16 | 4.26e-02 | -0.293000 | 1.15e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 28 | 7.51e-03 | -0.292000 | 3.50e-02 |
| Cholesterol biosynthesis | 24 | 1.36e-02 | 0.291000 | 5.41e-02 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 48 | 4.85e-04 | -0.291000 | 5.73e-03 |
| p38MAPK events | 11 | 9.51e-02 | -0.291000 | 1.95e-01 |
| AKT phosphorylates targets in the cytosol | 13 | 6.98e-02 | -0.290000 | 1.59e-01 |
| Intrinsic Pathway for Apoptosis | 46 | 6.59e-04 | -0.290000 | 6.85e-03 |
| Pre-NOTCH Expression and Processing | 47 | 5.81e-04 | -0.290000 | 6.40e-03 |
| Interactions of Rev with host cellular proteins | 36 | 2.60e-03 | -0.290000 | 1.77e-02 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 14 | 6.06e-02 | -0.290000 | 1.46e-01 |
| G beta:gamma signalling through PLC beta | 12 | 8.28e-02 | -0.289000 | 1.78e-01 |
| Presynaptic function of Kainate receptors | 12 | 8.28e-02 | -0.289000 | 1.78e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 1.14e-01 | -0.289000 | 2.26e-01 |
| SUMOylation of SUMOylation proteins | 34 | 3.69e-03 | -0.288000 | 2.25e-02 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 9.85e-02 | -0.288000 | 2.01e-01 |
| Transcriptional regulation by small RNAs | 46 | 7.40e-04 | -0.288000 | 7.39e-03 |
| Signaling by TGF-beta Receptor Complex | 71 | 2.88e-05 | -0.287000 | 5.43e-04 |
| Signaling by FGFR4 | 30 | 6.54e-03 | -0.287000 | 3.24e-02 |
| CaM pathway | 26 | 1.15e-02 | -0.286000 | 4.87e-02 |
| Calmodulin induced events | 26 | 1.15e-02 | -0.286000 | 4.87e-02 |
| CTLA4 inhibitory signaling | 16 | 4.77e-02 | -0.286000 | 1.23e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 15 | 5.64e-02 | -0.285000 | 1.39e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 4.90e-02 | -0.284000 | 1.26e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 3.20e-02 | -0.284000 | 9.64e-02 |
| Viral Messenger RNA Synthesis | 42 | 1.49e-03 | -0.283000 | 1.22e-02 |
| Formation of the Early Elongation Complex | 29 | 8.33e-03 | -0.283000 | 3.77e-02 |
| Formation of the HIV-1 Early Elongation Complex | 29 | 8.33e-03 | -0.283000 | 3.77e-02 |
| Transport of the SLBP Dependant Mature mRNA | 35 | 3.76e-03 | -0.283000 | 2.29e-02 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 15 | 5.83e-02 | 0.282000 | 1.43e-01 |
| RAF activation | 32 | 5.76e-03 | -0.282000 | 2.97e-02 |
| FOXO-mediated transcription of cell cycle genes | 15 | 5.90e-02 | -0.282000 | 1.45e-01 |
| Nucleobase biosynthesis | 15 | 5.92e-02 | -0.281000 | 1.45e-01 |
| Signaling by high-kinase activity BRAF mutants | 27 | 1.15e-02 | -0.281000 | 4.87e-02 |
| Activation of GABAB receptors | 22 | 2.26e-02 | -0.281000 | 7.55e-02 |
| GABA B receptor activation | 22 | 2.26e-02 | -0.281000 | 7.55e-02 |
| FCGR3A-mediated phagocytosis | 48 | 7.62e-04 | -0.281000 | 7.39e-03 |
| Leishmania phagocytosis | 48 | 7.62e-04 | -0.281000 | 7.39e-03 |
| Parasite infection | 48 | 7.62e-04 | -0.281000 | 7.39e-03 |
| Glucose metabolism | 76 | 2.34e-05 | -0.281000 | 4.62e-04 |
| Formation of the beta-catenin:TCF transactivating complex | 31 | 6.94e-03 | -0.280000 | 3.33e-02 |
| Signaling by FGFR3 | 32 | 6.17e-03 | -0.280000 | 3.15e-02 |
| VEGFR2 mediated vascular permeability | 23 | 2.04e-02 | -0.279000 | 7.10e-02 |
| SUMOylation of DNA replication proteins | 45 | 1.19e-03 | -0.279000 | 1.03e-02 |
| Ras activation upon Ca2+ influx through NMDA receptor | 13 | 8.17e-02 | -0.279000 | 1.77e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 12 | 9.48e-02 | -0.279000 | 1.95e-01 |
| DCC mediated attractive signaling | 13 | 8.22e-02 | -0.278000 | 1.78e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 63 | 1.38e-04 | -0.278000 | 2.21e-03 |
| Diseases associated with glycosylation precursor biosynthesis | 17 | 4.76e-02 | -0.278000 | 1.23e-01 |
| GRB2 events in ERBB2 signaling | 11 | 1.12e-01 | -0.277000 | 2.23e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 53 | 4.97e-04 | -0.277000 | 5.77e-03 |
| HIV Life Cycle | 135 | 3.04e-08 | -0.276000 | 1.32e-06 |
| rRNA processing in the nucleus and cytosol | 185 | 9.62e-11 | 0.276000 | 5.95e-09 |
| N-glycan antennae elongation in the medial/trans-Golgi | 22 | 2.51e-02 | 0.276000 | 8.07e-02 |
| RHO GTPases activate PAKs | 19 | 3.87e-02 | -0.274000 | 1.08e-01 |
| Nitric oxide stimulates guanylate cyclase | 13 | 8.77e-02 | 0.274000 | 1.84e-01 |
| Nuclear import of Rev protein | 33 | 6.55e-03 | -0.274000 | 3.24e-02 |
| Surfactant metabolism | 10 | 1.34e-01 | -0.273000 | 2.56e-01 |
| Assembly Of The HIV Virion | 16 | 5.86e-02 | -0.273000 | 1.44e-01 |
| RHOBTB3 ATPase cycle | 10 | 1.36e-01 | -0.273000 | 2.57e-01 |
| Budding and maturation of HIV virion | 28 | 1.27e-02 | -0.272000 | 5.23e-02 |
| Gene Silencing by RNA | 65 | 1.51e-04 | -0.272000 | 2.30e-03 |
| Rev-mediated nuclear export of HIV RNA | 34 | 6.27e-03 | -0.271000 | 3.17e-02 |
| NRAGE signals death through JNK | 47 | 1.33e-03 | -0.271000 | 1.11e-02 |
| Transport of the SLBP independent Mature mRNA | 34 | 6.34e-03 | -0.271000 | 3.20e-02 |
| The citric acid (TCA) cycle and respiratory electron transport | 147 | 1.56e-08 | -0.270000 | 6.98e-07 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 42 | 2.44e-03 | -0.270000 | 1.70e-02 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 25 | 1.97e-02 | -0.270000 | 6.93e-02 |
| SHC1 events in ERBB2 signaling | 16 | 6.23e-02 | -0.269000 | 1.47e-01 |
| SUMOylation of intracellular receptors | 27 | 1.58e-02 | -0.268000 | 5.84e-02 |
| Rho GTPase cycle | 128 | 1.76e-07 | -0.268000 | 6.74e-06 |
| Estrogen-dependent gene expression | 86 | 1.83e-05 | -0.267000 | 3.71e-04 |
| NS1 Mediated Effects on Host Pathways | 39 | 3.89e-03 | -0.267000 | 2.32e-02 |
| RMTs methylate histone arginines | 29 | 1.29e-02 | -0.267000 | 5.27e-02 |
| Ca-dependent events | 28 | 1.47e-02 | -0.266000 | 5.60e-02 |
| Gap junction trafficking and regulation | 16 | 6.51e-02 | -0.266000 | 1.51e-01 |
| BBSome-mediated cargo-targeting to cilium | 21 | 3.53e-02 | 0.265000 | 1.02e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 32 | 9.40e-03 | -0.265000 | 4.20e-02 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 1.12e-01 | 0.265000 | 2.23e-01 |
| Pyruvate metabolism | 26 | 1.95e-02 | -0.265000 | 6.92e-02 |
| RORA activates gene expression | 18 | 5.20e-02 | -0.265000 | 1.31e-01 |
| Chaperonin-mediated protein folding | 69 | 1.47e-04 | -0.264000 | 2.30e-03 |
| GAB1 signalosome | 14 | 8.69e-02 | -0.264000 | 1.83e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 5.95e-02 | -0.264000 | 1.45e-01 |
| Insulin receptor recycling | 19 | 4.65e-02 | -0.264000 | 1.21e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 4.65e-02 | -0.264000 | 1.21e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 30 | 1.25e-02 | -0.264000 | 5.21e-02 |
| Signaling by BRAF and RAF fusions | 53 | 9.24e-04 | -0.263000 | 8.60e-03 |
| Formation of apoptosome | 11 | 1.31e-01 | -0.263000 | 2.50e-01 |
| Regulation of the apoptosome activity | 11 | 1.31e-01 | -0.263000 | 2.50e-01 |
| The phototransduction cascade | 17 | 6.09e-02 | -0.263000 | 1.47e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 4.22e-02 | -0.262000 | 1.14e-01 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 103 | 4.32e-06 | -0.262000 | 1.06e-04 |
| ERK/MAPK targets | 22 | 3.36e-02 | -0.262000 | 9.85e-02 |
| Late Phase of HIV Life Cycle | 124 | 5.01e-07 | -0.262000 | 1.76e-05 |
| G0 and Early G1 | 27 | 1.87e-02 | -0.261000 | 6.68e-02 |
| Nucleotide salvage | 20 | 4.30e-02 | -0.261000 | 1.15e-01 |
| Cristae formation | 13 | 1.03e-01 | -0.261000 | 2.07e-01 |
| SUMOylation of RNA binding proteins | 44 | 2.74e-03 | -0.261000 | 1.79e-02 |
| G1/S-Specific Transcription | 29 | 1.54e-02 | -0.260000 | 5.79e-02 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 11 | 1.36e-01 | -0.260000 | 2.57e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 18 | 5.65e-02 | -0.260000 | 1.39e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 41 | 4.03e-03 | -0.260000 | 2.38e-02 |
| Mitotic Telophase/Cytokinesis | 13 | 1.05e-01 | -0.260000 | 2.11e-01 |
| FGFR2 mutant receptor activation | 20 | 4.44e-02 | -0.260000 | 1.17e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 29 | 1.56e-02 | -0.260000 | 5.80e-02 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 29 | 1.56e-02 | -0.260000 | 5.80e-02 |
| Respiratory electron transport | 98 | 9.09e-06 | -0.260000 | 1.97e-04 |
| Influenza Infection | 148 | 5.77e-08 | 0.259000 | 2.34e-06 |
| Diseases of programmed cell death | 25 | 2.56e-02 | -0.258000 | 8.19e-02 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 33 | 1.04e-02 | -0.258000 | 4.53e-02 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 21 | 4.14e-02 | -0.257000 | 1.13e-01 |
| Export of Viral Ribonucleoproteins from Nucleus | 31 | 1.32e-02 | -0.257000 | 5.31e-02 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 31 | 1.32e-02 | -0.257000 | 5.31e-02 |
| Processing and activation of SUMO | 10 | 1.59e-01 | -0.257000 | 2.83e-01 |
| Chromatin modifying enzymes | 191 | 1.06e-09 | -0.256000 | 5.52e-08 |
| Chromatin organization | 191 | 1.06e-09 | -0.256000 | 5.52e-08 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 71 | 1.92e-04 | -0.256000 | 2.77e-03 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 30 | 1.53e-02 | -0.256000 | 5.77e-02 |
| Oncogenic MAPK signaling | 69 | 2.49e-04 | -0.255000 | 3.28e-03 |
| Apoptotic factor-mediated response | 16 | 7.74e-02 | -0.255000 | 1.70e-01 |
| Glucagon signaling in metabolic regulation | 21 | 4.36e-02 | -0.254000 | 1.16e-01 |
| SHC-mediated cascade:FGFR1 | 11 | 1.46e-01 | -0.253000 | 2.68e-01 |
| Inwardly rectifying K+ channels | 16 | 8.02e-02 | -0.253000 | 1.75e-01 |
| SUMOylation of chromatin organization proteins | 54 | 1.34e-03 | -0.252000 | 1.11e-02 |
| Post NMDA receptor activation events | 48 | 2.53e-03 | -0.252000 | 1.75e-02 |
| Polymerase switching on the C-strand of the telomere | 24 | 3.29e-02 | -0.252000 | 9.74e-02 |
| mRNA Capping | 26 | 2.66e-02 | -0.251000 | 8.38e-02 |
| Signaling by FGFR2 IIIa TM | 18 | 6.52e-02 | -0.251000 | 1.51e-01 |
| Signaling by RAF1 mutants | 31 | 1.56e-02 | -0.251000 | 5.80e-02 |
| Protein folding | 75 | 1.76e-04 | -0.251000 | 2.67e-03 |
| Cytochrome c-mediated apoptotic response | 13 | 1.18e-01 | -0.251000 | 2.30e-01 |
| HDMs demethylate histones | 21 | 4.79e-02 | -0.249000 | 1.23e-01 |
| DAG and IP3 signaling | 32 | 1.47e-02 | -0.249000 | 5.60e-02 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 34 | 1.26e-02 | -0.247000 | 5.21e-02 |
| The NLRP3 inflammasome | 12 | 1.41e-01 | 0.246000 | 2.60e-01 |
| p75 NTR receptor-mediated signalling | 80 | 1.49e-04 | -0.245000 | 2.30e-03 |
| MECP2 regulates neuronal receptors and channels | 16 | 8.95e-02 | -0.245000 | 1.87e-01 |
| RHO GTPases Activate ROCKs | 17 | 8.09e-02 | -0.245000 | 1.76e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 26 | 3.22e-02 | -0.243000 | 9.65e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE | 24 | 4.02e-02 | -0.242000 | 1.11e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 24 | 4.02e-02 | -0.242000 | 1.11e-01 |
| Interleukin-6 family signaling | 20 | 6.33e-02 | 0.240000 | 1.49e-01 |
| Signaling by FGFR | 67 | 6.91e-04 | -0.240000 | 7.13e-03 |
| Epigenetic regulation of gene expression | 79 | 2.38e-04 | -0.239000 | 3.22e-03 |
| Signaling by ERBB2 | 41 | 8.35e-03 | -0.238000 | 3.77e-02 |
| IKK complex recruitment mediated by RIP1 | 21 | 5.93e-02 | -0.238000 | 1.45e-01 |
| Signaling by EGFR | 45 | 5.84e-03 | -0.238000 | 2.99e-02 |
| Signal amplification | 22 | 5.45e-02 | -0.237000 | 1.35e-01 |
| Striated Muscle Contraction | 10 | 1.97e-01 | -0.236000 | 3.32e-01 |
| Platelet degranulation | 81 | 2.48e-04 | -0.236000 | 3.28e-03 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 2.78e-03 | -0.235000 | 1.79e-02 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 2.78e-03 | -0.235000 | 1.79e-02 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 2.78e-03 | -0.235000 | 1.79e-02 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 2.78e-03 | -0.235000 | 1.79e-02 |
| Signaling by NOTCH1 in Cancer | 54 | 2.78e-03 | -0.235000 | 1.79e-02 |
| Post-translational protein phosphorylation | 68 | 8.04e-04 | 0.235000 | 7.69e-03 |
| Nicotinamide salvaging | 14 | 1.28e-01 | 0.235000 | 2.48e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 4.21e-02 | -0.235000 | 1.14e-01 |
| Recycling pathway of L1 | 28 | 3.17e-02 | -0.235000 | 9.61e-02 |
| Signaling by ROBO receptors | 200 | 1.15e-08 | 0.234000 | 5.35e-07 |
| Detoxification of Reactive Oxygen Species | 28 | 3.19e-02 | -0.234000 | 9.62e-02 |
| HIV Infection | 204 | 8.66e-09 | -0.234000 | 4.17e-07 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 2.43e-02 | -0.234000 | 7.88e-02 |
| Gap junction trafficking | 14 | 1.30e-01 | -0.233000 | 2.50e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 10 | 2.02e-01 | -0.233000 | 3.38e-01 |
| SUMOylation of DNA damage response and repair proteins | 71 | 7.19e-04 | -0.232000 | 7.36e-03 |
| PI Metabolism | 67 | 1.04e-03 | -0.232000 | 9.26e-03 |
| SHC1 events in ERBB4 signaling | 10 | 2.06e-01 | -0.231000 | 3.42e-01 |
| Transcriptional Regulation by MECP2 | 50 | 4.72e-03 | -0.231000 | 2.60e-02 |
| Transcription of the HIV genome | 59 | 2.22e-03 | -0.230000 | 1.62e-02 |
| Beta-catenin phosphorylation cascade | 17 | 1.01e-01 | -0.230000 | 2.04e-01 |
| Ca2+ pathway | 46 | 6.96e-03 | -0.230000 | 3.33e-02 |
| EPHA-mediated growth cone collapse | 13 | 1.51e-01 | -0.230000 | 2.75e-01 |
| MAP2K and MAPK activation | 31 | 2.68e-02 | -0.230000 | 8.42e-02 |
| Regulation of RUNX1 Expression and Activity | 17 | 1.02e-01 | -0.229000 | 2.06e-01 |
| Formation of RNA Pol II elongation complex | 50 | 5.07e-03 | -0.229000 | 2.70e-02 |
| RNA Polymerase II Transcription Elongation | 50 | 5.07e-03 | -0.229000 | 2.70e-02 |
| HSF1-dependent transactivation | 27 | 3.96e-02 | -0.229000 | 1.11e-01 |
| TGF-beta receptor signaling activates SMADs | 32 | 2.53e-02 | -0.229000 | 8.12e-02 |
| Diseases of DNA repair | 12 | 1.71e-01 | -0.228000 | 3.01e-01 |
| Biotin transport and metabolism | 11 | 1.91e-01 | -0.228000 | 3.27e-01 |
| GABA receptor activation | 27 | 4.04e-02 | -0.228000 | 1.11e-01 |
| Collagen degradation | 28 | 3.70e-02 | 0.228000 | 1.05e-01 |
| Leading Strand Synthesis | 14 | 1.41e-01 | -0.227000 | 2.60e-01 |
| Polymerase switching | 14 | 1.41e-01 | -0.227000 | 2.60e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 16 | 1.16e-01 | -0.227000 | 2.28e-01 |
| ESR-mediated signaling | 140 | 3.56e-06 | -0.227000 | 9.26e-05 |
| Lagging Strand Synthesis | 20 | 7.90e-02 | -0.227000 | 1.73e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 18 | 9.57e-02 | -0.227000 | 1.96e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 27 | 4.16e-02 | -0.227000 | 1.13e-01 |
| E2F mediated regulation of DNA replication | 21 | 7.27e-02 | -0.226000 | 1.63e-01 |
| FRS-mediated FGFR4 signaling | 11 | 1.95e-01 | -0.226000 | 3.32e-01 |
| Disorders of Developmental Biology | 13 | 1.59e-01 | -0.226000 | 2.83e-01 |
| Disorders of Nervous System Development | 13 | 1.59e-01 | -0.226000 | 2.83e-01 |
| Loss of function of MECP2 in Rett syndrome | 13 | 1.59e-01 | -0.226000 | 2.83e-01 |
| Pervasive developmental disorders | 13 | 1.59e-01 | -0.226000 | 2.83e-01 |
| Aquaporin-mediated transport | 27 | 4.26e-02 | -0.226000 | 1.15e-01 |
| Downstream signaling of activated FGFR1 | 20 | 8.11e-02 | -0.225000 | 1.76e-01 |
| Response to elevated platelet cytosolic Ca2+ | 85 | 3.52e-04 | -0.224000 | 4.44e-03 |
| Mitochondrial calcium ion transport | 21 | 7.54e-02 | -0.224000 | 1.67e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 18 | 1.00e-01 | 0.224000 | 2.04e-01 |
| Signaling by Rho GTPases | 334 | 2.49e-12 | -0.223000 | 1.70e-10 |
| CDC6 association with the ORC:origin complex | 11 | 2.00e-01 | -0.223000 | 3.36e-01 |
| RET signaling | 33 | 2.74e-02 | -0.222000 | 8.57e-02 |
| Signaling by ERBB2 ECD mutants | 14 | 1.51e-01 | -0.222000 | 2.75e-01 |
| Platelet activation, signaling and aggregation | 172 | 5.32e-07 | -0.222000 | 1.82e-05 |
| Hyaluronan metabolism | 13 | 1.66e-01 | -0.222000 | 2.94e-01 |
| Plasma lipoprotein remodeling | 13 | 1.69e-01 | 0.221000 | 2.98e-01 |
| Protein ubiquitination | 62 | 2.75e-03 | -0.220000 | 1.79e-02 |
| Apoptotic cleavage of cellular proteins | 32 | 3.13e-02 | -0.220000 | 9.53e-02 |
| PLC beta mediated events | 39 | 1.77e-02 | -0.220000 | 6.45e-02 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 26 | 5.37e-02 | -0.219000 | 1.34e-01 |
| Signaling by FGFR3 in disease | 14 | 1.57e-01 | -0.219000 | 2.82e-01 |
| Signaling by FGFR3 point mutants in cancer | 14 | 1.57e-01 | -0.219000 | 2.82e-01 |
| Transcriptional regulation of white adipocyte differentiation | 73 | 1.25e-03 | -0.219000 | 1.06e-02 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 31 | 3.55e-02 | 0.218000 | 1.02e-01 |
| Plasma lipoprotein assembly | 10 | 2.32e-01 | 0.218000 | 3.73e-01 |
| Response of Mtb to phagocytosis | 20 | 9.17e-02 | -0.218000 | 1.89e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 18 | 1.10e-01 | -0.218000 | 2.19e-01 |
| COPI-mediated anterograde transport | 76 | 1.04e-03 | -0.218000 | 9.26e-03 |
| HATs acetylate histones | 77 | 9.68e-04 | -0.218000 | 8.89e-03 |
| Signaling by FGFR2 in disease | 29 | 4.28e-02 | -0.217000 | 1.15e-01 |
| Peptide ligand-binding receptors | 53 | 6.22e-03 | 0.217000 | 3.16e-02 |
| Polo-like kinase mediated events | 16 | 1.32e-01 | -0.217000 | 2.53e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease | 14 | 1.59e-01 | -0.217000 | 2.83e-01 |
| Telomere Maintenance | 62 | 3.11e-03 | -0.217000 | 1.94e-02 |
| DARPP-32 events | 23 | 7.22e-02 | -0.217000 | 1.63e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 75 | 1.21e-03 | 0.216000 | 1.04e-02 |
| DNA strand elongation | 32 | 3.47e-02 | -0.216000 | 1.01e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 30 | 4.12e-02 | -0.215000 | 1.13e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 11 | 2.17e-01 | -0.215000 | 3.57e-01 |
| Molecules associated with elastic fibres | 25 | 6.32e-02 | 0.215000 | 1.49e-01 |
| STING mediated induction of host immune responses | 10 | 2.40e-01 | 0.214000 | 3.81e-01 |
| RHO GTPase Effectors | 217 | 5.69e-08 | -0.214000 | 2.34e-06 |
| Regulation of innate immune responses to cytosolic DNA | 11 | 2.20e-01 | 0.214000 | 3.58e-01 |
| Cleavage of the damaged pyrimidine | 16 | 1.39e-01 | -0.214000 | 2.60e-01 |
| Depyrimidination | 16 | 1.39e-01 | -0.214000 | 2.60e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 16 | 1.39e-01 | -0.214000 | 2.60e-01 |
| Semaphorin interactions | 53 | 7.23e-03 | -0.213000 | 3.42e-02 |
| HCMV Early Events | 58 | 4.99e-03 | -0.213000 | 2.68e-02 |
| Transcriptional Regulation by E2F6 | 31 | 4.02e-02 | -0.213000 | 1.11e-01 |
| Opioid Signalling | 66 | 2.80e-03 | -0.213000 | 1.79e-02 |
| Downstream signaling of activated FGFR3 | 17 | 1.30e-01 | -0.212000 | 2.50e-01 |
| Glycolysis | 61 | 4.25e-03 | -0.212000 | 2.44e-02 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 25 | 6.70e-02 | -0.212000 | 1.54e-01 |
| SUMO E3 ligases SUMOylate target proteins | 155 | 5.56e-06 | -0.212000 | 1.34e-04 |
| Amyloid fiber formation | 35 | 3.12e-02 | -0.211000 | 9.52e-02 |
| EPH-Ephrin signaling | 83 | 9.26e-04 | -0.210000 | 8.60e-03 |
| Signaling by NOTCH1 | 68 | 2.72e-03 | -0.210000 | 1.79e-02 |
| Signaling by FGFR2 | 56 | 6.57e-03 | -0.210000 | 3.24e-02 |
| ECM proteoglycans | 40 | 2.18e-02 | 0.210000 | 7.45e-02 |
| COPI-dependent Golgi-to-ER retrograde traffic | 74 | 1.87e-03 | -0.209000 | 1.43e-02 |
| Activation of HOX genes during differentiation | 55 | 7.32e-03 | -0.209000 | 3.43e-02 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 55 | 7.32e-03 | -0.209000 | 3.43e-02 |
| NoRC negatively regulates rRNA expression | 41 | 2.06e-02 | -0.209000 | 7.13e-02 |
| The activation of arylsulfatases | 10 | 2.54e-01 | 0.208000 | 3.97e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 1.17e-01 | -0.208000 | 2.30e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 29 | 5.27e-02 | -0.208000 | 1.32e-01 |
| FRS-mediated FGFR1 signaling | 13 | 1.95e-01 | -0.207000 | 3.32e-01 |
| Complement cascade | 14 | 1.79e-01 | 0.207000 | 3.12e-01 |
| Regulation of Complement cascade | 14 | 1.79e-01 | 0.207000 | 3.12e-01 |
| Oncogene Induced Senescence | 32 | 4.26e-02 | -0.207000 | 1.15e-01 |
| EPH-ephrin mediated repulsion of cells | 44 | 1.75e-02 | -0.207000 | 6.44e-02 |
| Negative epigenetic regulation of rRNA expression | 44 | 1.77e-02 | -0.207000 | 6.45e-02 |
| Signaling by KIT in disease | 17 | 1.40e-01 | 0.207000 | 2.60e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 17 | 1.40e-01 | 0.207000 | 2.60e-01 |
| Host Interactions of HIV factors | 114 | 1.41e-04 | -0.207000 | 2.23e-03 |
| Signaling by Insulin receptor | 53 | 9.50e-03 | -0.206000 | 4.21e-02 |
| Glutamate and glutamine metabolism | 12 | 2.19e-01 | -0.205000 | 3.58e-01 |
| Factors involved in megakaryocyte development and platelet production | 106 | 2.77e-04 | -0.205000 | 3.56e-03 |
| SUMOylation | 161 | 7.72e-06 | -0.205000 | 1.70e-04 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 12 | 2.20e-01 | -0.204000 | 3.58e-01 |
| NCAM1 interactions | 27 | 6.64e-02 | 0.204000 | 1.53e-01 |
| Diseases associated with glycosaminoglycan metabolism | 32 | 4.58e-02 | 0.204000 | 1.20e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 7.21e-02 | -0.204000 | 1.63e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 35 | 3.74e-02 | -0.203000 | 1.05e-01 |
| FGFR2 alternative splicing | 24 | 8.47e-02 | -0.203000 | 1.80e-01 |
| Chondroitin sulfate biosynthesis | 16 | 1.61e-01 | 0.202000 | 2.86e-01 |
| FOXO-mediated transcription | 51 | 1.25e-02 | -0.202000 | 5.21e-02 |
| Lysosome Vesicle Biogenesis | 33 | 4.55e-02 | -0.201000 | 1.20e-01 |
| Negative regulation of MAPK pathway | 40 | 2.81e-02 | -0.201000 | 8.76e-02 |
| Metabolism of non-coding RNA | 51 | 1.33e-02 | -0.201000 | 5.31e-02 |
| snRNP Assembly | 51 | 1.33e-02 | -0.201000 | 5.31e-02 |
| Long-term potentiation | 14 | 1.97e-01 | -0.199000 | 3.32e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 16 | 1.69e-01 | -0.199000 | 2.98e-01 |
| LDL clearance | 15 | 1.84e-01 | -0.198000 | 3.18e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 14 | 2.00e-01 | -0.198000 | 3.36e-01 |
| Unwinding of DNA | 12 | 2.38e-01 | -0.197000 | 3.79e-01 |
| Signaling by ERBB2 KD Mutants | 19 | 1.38e-01 | -0.197000 | 2.59e-01 |
| Signaling by NODAL | 11 | 2.59e-01 | -0.197000 | 4.02e-01 |
| Synthesis of PIPs at the plasma membrane | 43 | 2.58e-02 | -0.197000 | 8.20e-02 |
| Branched-chain amino acid catabolism | 20 | 1.28e-01 | -0.196000 | 2.48e-01 |
| STAT5 activation downstream of FLT3 ITD mutants | 10 | 2.82e-01 | -0.196000 | 4.27e-01 |
| Cyclin D associated events in G1 | 41 | 3.02e-02 | -0.196000 | 9.28e-02 |
| G1 Phase | 41 | 3.02e-02 | -0.196000 | 9.28e-02 |
| PI3K/AKT Signaling in Cancer | 71 | 4.39e-03 | -0.196000 | 2.48e-02 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 6.43e-02 | -0.195000 | 1.50e-01 |
| Receptor Mediated Mitophagy | 10 | 2.85e-01 | -0.195000 | 4.29e-01 |
| MHC class II antigen presentation | 82 | 2.28e-03 | -0.195000 | 1.65e-02 |
| rRNA processing | 211 | 1.09e-06 | 0.195000 | 3.44e-05 |
| Base-Excision Repair, AP Site Formation | 18 | 1.52e-01 | -0.195000 | 2.75e-01 |
| Regulation of lipid metabolism by PPARalpha | 106 | 5.37e-04 | -0.195000 | 6.04e-03 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 12 | 2.44e-01 | -0.194000 | 3.86e-01 |
| Golgi-to-ER retrograde transport | 107 | 5.39e-04 | -0.194000 | 6.04e-03 |
| Transport of vitamins, nucleosides, and related molecules | 29 | 7.10e-02 | -0.194000 | 1.61e-01 |
| Signaling by ERBB2 in Cancer | 20 | 1.34e-01 | -0.193000 | 2.56e-01 |
| Infection with Mycobacterium tuberculosis | 21 | 1.25e-01 | -0.193000 | 2.43e-01 |
| PKA activation in glucagon signalling | 12 | 2.47e-01 | -0.193000 | 3.88e-01 |
| Downregulation of ERBB2 signaling | 23 | 1.09e-01 | -0.193000 | 2.18e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 38 | 3.97e-02 | -0.193000 | 1.11e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 1.82e-01 | -0.193000 | 3.16e-01 |
| HCMV Infection | 82 | 2.58e-03 | -0.193000 | 1.77e-02 |
| Chromosome Maintenance | 88 | 1.86e-03 | -0.192000 | 1.43e-02 |
| Signaling by FGFR in disease | 48 | 2.15e-02 | -0.192000 | 7.39e-02 |
| Mitotic Prophase | 81 | 2.88e-03 | -0.192000 | 1.84e-02 |
| G-protein mediated events | 40 | 3.61e-02 | -0.192000 | 1.03e-01 |
| S Phase | 153 | 4.44e-05 | -0.191000 | 8.02e-04 |
| RNA Polymerase II Pre-transcription Events | 70 | 5.80e-03 | -0.191000 | 2.98e-02 |
| Acyl chain remodelling of PS | 10 | 2.96e-01 | 0.191000 | 4.43e-01 |
| Constitutive Signaling by EGFRvIII | 13 | 2.34e-01 | -0.191000 | 3.75e-01 |
| Signaling by EGFRvIII in Cancer | 13 | 2.34e-01 | -0.191000 | 3.75e-01 |
| Membrane binding and targetting of GAG proteins | 14 | 2.18e-01 | -0.190000 | 3.57e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 2.18e-01 | -0.190000 | 3.57e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 23 | 1.15e-01 | 0.190000 | 2.27e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 330 | 3.58e-09 | -0.189000 | 1.79e-07 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 13 | 2.37e-01 | -0.189000 | 3.79e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 28 | 8.31e-02 | -0.189000 | 1.78e-01 |
| Nuclear Envelope Breakdown | 51 | 1.97e-02 | -0.189000 | 6.93e-02 |
| Extra-nuclear estrogen signaling | 57 | 1.38e-02 | -0.189000 | 5.45e-02 |
| RHO GTPases Activate Formins | 115 | 4.80e-04 | -0.189000 | 5.73e-03 |
| Sphingolipid de novo biosynthesis | 38 | 4.43e-02 | -0.189000 | 1.17e-01 |
| PERK regulates gene expression | 31 | 6.93e-02 | 0.189000 | 1.59e-01 |
| Purine salvage | 12 | 2.60e-01 | -0.188000 | 4.03e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 43 | 3.36e-02 | 0.187000 | 9.85e-02 |
| Signaling by WNT | 224 | 1.51e-06 | -0.187000 | 4.55e-05 |
| Costimulation by the CD28 family | 40 | 4.15e-02 | -0.186000 | 1.13e-01 |
| PPARA activates gene expression | 104 | 1.07e-03 | -0.186000 | 9.48e-03 |
| Phosphorylation of the APC/C | 20 | 1.51e-01 | -0.186000 | 2.75e-01 |
| Clathrin-mediated endocytosis | 125 | 3.43e-04 | -0.186000 | 4.38e-03 |
| G2/M DNA damage checkpoint | 57 | 1.58e-02 | -0.185000 | 5.84e-02 |
| activated TAK1 mediates p38 MAPK activation | 18 | 1.75e-01 | -0.185000 | 3.06e-01 |
| cGMP effects | 10 | 3.14e-01 | 0.184000 | 4.62e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 16 | 2.03e-01 | 0.184000 | 3.40e-01 |
| NR1H2 and NR1H3-mediated signaling | 34 | 6.40e-02 | -0.184000 | 1.50e-01 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 2.93e-01 | -0.183000 | 4.39e-01 |
| Nucleotide Excision Repair | 106 | 1.14e-03 | -0.183000 | 1.00e-02 |
| Mitotic Metaphase and Anaphase | 216 | 3.88e-06 | -0.183000 | 9.90e-05 |
| HSF1 activation | 21 | 1.48e-01 | -0.183000 | 2.70e-01 |
| Mitotic Anaphase | 215 | 4.20e-06 | -0.182000 | 1.05e-04 |
| Activation of the pre-replicative complex | 33 | 7.00e-02 | -0.182000 | 1.59e-01 |
| Vitamin D (calciferol) metabolism | 10 | 3.19e-01 | -0.182000 | 4.67e-01 |
| Smooth Muscle Contraction | 29 | 9.06e-02 | -0.182000 | 1.89e-01 |
| Regulation of FZD by ubiquitination | 17 | 1.95e-01 | 0.181000 | 3.32e-01 |
| Integrin signaling | 22 | 1.41e-01 | -0.181000 | 2.61e-01 |
| Platelet Aggregation (Plug Formation) | 22 | 1.41e-01 | -0.181000 | 2.61e-01 |
| Insulin receptor signalling cascade | 35 | 6.40e-02 | -0.181000 | 1.50e-01 |
| Formation of Incision Complex in GG-NER | 41 | 4.55e-02 | -0.181000 | 1.20e-01 |
| Phospholipid metabolism | 155 | 1.07e-04 | -0.180000 | 1.81e-03 |
| Meiotic synapsis | 26 | 1.12e-01 | -0.180000 | 2.23e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 16 | 2.13e-01 | -0.180000 | 3.52e-01 |
| SHC-mediated cascade:FGFR2 | 10 | 3.26e-01 | -0.179000 | 4.71e-01 |
| Resolution of D-Loop Structures | 31 | 8.51e-02 | -0.179000 | 1.81e-01 |
| Homologous DNA Pairing and Strand Exchange | 41 | 4.79e-02 | -0.179000 | 1.23e-01 |
| Signaling by TGFB family members | 91 | 3.33e-03 | -0.178000 | 2.06e-02 |
| HDACs deacetylate histones | 30 | 9.14e-02 | -0.178000 | 1.89e-01 |
| Meiosis | 47 | 3.49e-02 | -0.178000 | 1.01e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 16 | 2.18e-01 | 0.178000 | 3.57e-01 |
| TBC/RABGAPs | 42 | 4.67e-02 | -0.177000 | 1.21e-01 |
| Regulation of IFNG signaling | 11 | 3.09e-01 | 0.177000 | 4.58e-01 |
| Attenuation phase | 19 | 1.81e-01 | -0.177000 | 3.16e-01 |
| Carboxyterminal post-translational modifications of tubulin | 26 | 1.18e-01 | -0.177000 | 2.30e-01 |
| Cellular Senescence | 123 | 7.26e-04 | -0.177000 | 7.37e-03 |
| Apoptotic execution phase | 40 | 5.35e-02 | -0.177000 | 1.34e-01 |
| Deadenylation of mRNA | 22 | 1.52e-01 | -0.177000 | 2.75e-01 |
| Signaling by Nuclear Receptors | 191 | 3.00e-05 | -0.175000 | 5.50e-04 |
| Meiotic recombination | 23 | 1.46e-01 | -0.175000 | 2.68e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 30 | 9.73e-02 | -0.175000 | 1.98e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 3.17e-01 | -0.174000 | 4.66e-01 |
| FOXO-mediated transcription of cell death genes | 15 | 2.43e-01 | -0.174000 | 3.85e-01 |
| Regulated proteolysis of p75NTR | 10 | 3.42e-01 | -0.173000 | 4.89e-01 |
| RIP-mediated NFkB activation via ZBP1 | 15 | 2.47e-01 | 0.173000 | 3.88e-01 |
| Transcriptional Regulation by VENTX | 36 | 7.33e-02 | -0.173000 | 1.64e-01 |
| Cellular response to heat stress | 87 | 5.50e-03 | -0.172000 | 2.86e-02 |
| RHO GTPases activate CIT | 17 | 2.19e-01 | -0.172000 | 3.58e-01 |
| Downregulation of TGF-beta receptor signaling | 26 | 1.29e-01 | -0.172000 | 2.48e-01 |
| Signaling by MET | 60 | 2.13e-02 | -0.172000 | 7.36e-02 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 2.83e-01 | -0.172000 | 4.27e-01 |
| Insulin processing | 22 | 1.64e-01 | -0.171000 | 2.91e-01 |
| O-glycosylation of TSR domain-containing proteins | 30 | 1.05e-01 | 0.171000 | 2.11e-01 |
| Metalloprotease DUBs | 20 | 1.87e-01 | -0.171000 | 3.21e-01 |
| GPVI-mediated activation cascade | 21 | 1.77e-01 | -0.170000 | 3.10e-01 |
| Class A/1 (Rhodopsin-like receptors) | 97 | 3.84e-03 | 0.170000 | 2.32e-02 |
| PIWI-interacting RNA (piRNA) biogenesis | 17 | 2.26e-01 | -0.170000 | 3.65e-01 |
| Extension of Telomeres | 49 | 4.06e-02 | -0.169000 | 1.12e-01 |
| Purine catabolism | 15 | 2.57e-01 | -0.169000 | 4.00e-01 |
| FCGR3A-mediated IL10 synthesis | 26 | 1.36e-01 | -0.169000 | 2.58e-01 |
| HIV Transcription Initiation | 41 | 6.17e-02 | -0.169000 | 1.47e-01 |
| RNA Polymerase II HIV Promoter Escape | 41 | 6.17e-02 | -0.169000 | 1.47e-01 |
| RNA Polymerase II Promoter Escape | 41 | 6.17e-02 | -0.169000 | 1.47e-01 |
| RNA Polymerase II Transcription Initiation | 41 | 6.17e-02 | -0.169000 | 1.47e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 41 | 6.17e-02 | -0.169000 | 1.47e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 41 | 6.17e-02 | -0.169000 | 1.47e-01 |
| Regulation of PTEN gene transcription | 57 | 2.78e-02 | -0.169000 | 8.69e-02 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 60 | 2.44e-02 | -0.168000 | 7.88e-02 |
| Circadian Clock | 65 | 1.93e-02 | -0.168000 | 6.85e-02 |
| Interferon gamma signaling | 54 | 3.31e-02 | 0.168000 | 9.79e-02 |
| PKA-mediated phosphorylation of CREB | 15 | 2.61e-01 | -0.168000 | 4.04e-01 |
| HCMV Late Events | 55 | 3.16e-02 | -0.168000 | 9.60e-02 |
| Acyl chain remodelling of PE | 12 | 3.15e-01 | 0.168000 | 4.63e-01 |
| Metabolism of nucleotides | 88 | 6.77e-03 | -0.167000 | 3.27e-02 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 46 | 5.01e-02 | -0.167000 | 1.28e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 61 | 2.42e-02 | -0.167000 | 7.87e-02 |
| RNA Polymerase III Transcription Initiation | 34 | 9.21e-02 | -0.167000 | 1.89e-01 |
| MAPK6/MAPK4 signaling | 80 | 1.01e-02 | -0.166000 | 4.42e-02 |
| Deadenylation-dependent mRNA decay | 51 | 3.98e-02 | -0.166000 | 1.11e-01 |
| ADP signalling through P2Y purinoceptor 1 | 17 | 2.35e-01 | -0.166000 | 3.76e-01 |
| Carnitine metabolism | 10 | 3.63e-01 | 0.166000 | 5.10e-01 |
| VEGFA-VEGFR2 Pathway | 82 | 9.45e-03 | -0.166000 | 4.21e-02 |
| Synthesis of IP2, IP, and Ins in the cytosol | 12 | 3.20e-01 | -0.166000 | 4.68e-01 |
| Acyl chain remodelling of PC | 13 | 3.02e-01 | 0.165000 | 4.49e-01 |
| Translation | 269 | 3.33e-06 | 0.165000 | 9.03e-05 |
| RHO GTPases Activate NADPH Oxidases | 16 | 2.54e-01 | -0.165000 | 3.97e-01 |
| Negative regulation of FLT3 | 13 | 3.06e-01 | -0.164000 | 4.55e-01 |
| Regulation of TP53 Activity through Acetylation | 27 | 1.41e-01 | -0.164000 | 2.60e-01 |
| Signal transduction by L1 | 20 | 2.05e-01 | -0.164000 | 3.42e-01 |
| Processing of DNA double-strand break ends | 62 | 2.59e-02 | -0.164000 | 8.20e-02 |
| Resolution of Abasic Sites (AP sites) | 37 | 8.53e-02 | -0.164000 | 1.81e-01 |
| Transcriptional activation of mitochondrial biogenesis | 52 | 4.15e-02 | -0.163000 | 1.13e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 11 | 3.48e-01 | -0.163000 | 4.97e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 81 | 1.11e-02 | -0.163000 | 4.79e-02 |
| Transcriptional Regulation by TP53 | 328 | 4.60e-07 | -0.162000 | 1.71e-05 |
| Oxidative Stress Induced Senescence | 61 | 2.84e-02 | -0.162000 | 8.83e-02 |
| Regulation of HSF1-mediated heat shock response | 71 | 1.81e-02 | -0.162000 | 6.53e-02 |
| Signaling by NOTCH2 | 28 | 1.38e-01 | -0.162000 | 2.59e-01 |
| Signaling by FGFR4 in disease | 10 | 3.75e-01 | -0.162000 | 5.21e-01 |
| RAF-independent MAPK1/3 activation | 22 | 1.89e-01 | 0.162000 | 3.24e-01 |
| Uptake and actions of bacterial toxins | 24 | 1.71e-01 | -0.162000 | 3.01e-01 |
| Death Receptor Signalling | 119 | 2.39e-03 | -0.161000 | 1.69e-02 |
| Hemostasis | 384 | 6.45e-08 | -0.161000 | 2.54e-06 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 12 | 3.35e-01 | -0.161000 | 4.82e-01 |
| DNA Replication | 122 | 2.30e-03 | -0.160000 | 1.65e-02 |
| MAP kinase activation | 61 | 3.11e-02 | -0.160000 | 9.51e-02 |
| Downstream signaling of activated FGFR4 | 16 | 2.71e-01 | -0.159000 | 4.17e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 1.78e-01 | -0.159000 | 3.11e-01 |
| MyD88-independent TLR4 cascade | 88 | 1.00e-02 | -0.159000 | 4.41e-02 |
| TRIF(TICAM1)-mediated TLR4 signaling | 88 | 1.00e-02 | -0.159000 | 4.41e-02 |
| Positive epigenetic regulation of rRNA expression | 41 | 7.95e-02 | -0.158000 | 1.73e-01 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 29 | 1.41e-01 | 0.158000 | 2.60e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 1.17e-01 | -0.158000 | 2.30e-01 |
| Signaling by BMP | 20 | 2.24e-01 | 0.157000 | 3.63e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 11 | 3.67e-01 | -0.157000 | 5.15e-01 |
| Processing of SMDT1 | 14 | 3.09e-01 | -0.157000 | 4.58e-01 |
| VxPx cargo-targeting to cilium | 16 | 2.78e-01 | -0.157000 | 4.23e-01 |
| MAPK family signaling cascades | 245 | 2.58e-05 | -0.156000 | 4.93e-04 |
| RNA Polymerase III Abortive And Retractive Initiation | 39 | 9.19e-02 | -0.156000 | 1.89e-01 |
| RNA Polymerase III Transcription | 39 | 9.19e-02 | -0.156000 | 1.89e-01 |
| Other semaphorin interactions | 12 | 3.50e-01 | 0.156000 | 4.98e-01 |
| PKA activation | 13 | 3.31e-01 | -0.156000 | 4.76e-01 |
| Synthesis of DNA | 114 | 4.30e-03 | -0.155000 | 2.45e-02 |
| Transport of Mature Transcript to Cytoplasm | 78 | 1.81e-02 | -0.155000 | 6.53e-02 |
| Signaling by PDGFRA extracellular domain mutants | 10 | 3.97e-01 | 0.155000 | 5.41e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 10 | 3.97e-01 | 0.155000 | 5.41e-01 |
| PI-3K cascade:FGFR3 | 11 | 3.74e-01 | -0.155000 | 5.21e-01 |
| Aggrephagy | 21 | 2.20e-01 | -0.155000 | 3.58e-01 |
| Rap1 signalling | 14 | 3.18e-01 | -0.154000 | 4.67e-01 |
| Retinoid metabolism and transport | 26 | 1.75e-01 | 0.154000 | 3.06e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 28 | 1.59e-01 | -0.154000 | 2.83e-01 |
| Cell Cycle | 578 | 3.50e-10 | -0.153000 | 2.07e-08 |
| TCF dependent signaling in response to WNT | 150 | 1.21e-03 | -0.153000 | 1.04e-02 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 43 | 8.31e-02 | 0.153000 | 1.78e-01 |
| Tight junction interactions | 14 | 3.23e-01 | 0.153000 | 4.70e-01 |
| Rab regulation of trafficking | 114 | 4.98e-03 | -0.152000 | 2.68e-02 |
| Base Excision Repair | 45 | 7.73e-02 | -0.152000 | 1.70e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 16 | 2.92e-01 | -0.152000 | 4.39e-01 |
| Signaling by VEGF | 90 | 1.31e-02 | -0.151000 | 5.31e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 15 | 3.12e-01 | -0.151000 | 4.60e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 47 | 7.36e-02 | -0.151000 | 1.64e-01 |
| HDR through Single Strand Annealing (SSA) | 36 | 1.18e-01 | -0.151000 | 2.30e-01 |
| FLT3 Signaling | 31 | 1.47e-01 | -0.151000 | 2.69e-01 |
| Interleukin-17 signaling | 65 | 3.60e-02 | -0.150000 | 1.03e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 16 | 3.00e-01 | -0.150000 | 4.48e-01 |
| Bile acid and bile salt metabolism | 25 | 1.97e-01 | -0.149000 | 3.33e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 22 | 2.29e-01 | 0.148000 | 3.68e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 83 | 2.05e-02 | -0.147000 | 7.12e-02 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 15 | 3.24e-01 | -0.147000 | 4.70e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 18 | 2.81e-01 | -0.147000 | 4.25e-01 |
| MyD88 dependent cascade initiated on endosome | 80 | 2.35e-02 | -0.147000 | 7.71e-02 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 80 | 2.35e-02 | -0.147000 | 7.71e-02 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 80 | 2.35e-02 | -0.147000 | 7.71e-02 |
| Interleukin-15 signaling | 11 | 4.01e-01 | 0.146000 | 5.44e-01 |
| Interleukin-2 family signaling | 25 | 2.07e-01 | 0.146000 | 3.44e-01 |
| Prolactin receptor signaling | 11 | 4.04e-01 | 0.145000 | 5.47e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 69 | 3.72e-02 | -0.145000 | 1.05e-01 |
| SUMOylation of immune response proteins | 11 | 4.05e-01 | -0.145000 | 5.48e-01 |
| Signaling by EGFR in Cancer | 21 | 2.51e-01 | -0.145000 | 3.93e-01 |
| Nuclear Events (kinase and transcription factor activation) | 56 | 6.23e-02 | -0.144000 | 1.47e-01 |
| Kinesins | 36 | 1.35e-01 | -0.144000 | 2.56e-01 |
| Activation of NMDA receptors and postsynaptic events | 58 | 5.90e-02 | -0.143000 | 1.45e-01 |
| Effects of PIP2 hydrolysis | 22 | 2.45e-01 | -0.143000 | 3.86e-01 |
| Negative regulation of the PI3K/AKT network | 75 | 3.21e-02 | -0.143000 | 9.65e-02 |
| Glycerophospholipid biosynthesis | 89 | 1.99e-02 | -0.143000 | 6.97e-02 |
| N-Glycan antennae elongation | 14 | 3.56e-01 | 0.143000 | 5.03e-01 |
| FRS-mediated FGFR2 signaling | 12 | 3.94e-01 | -0.142000 | 5.39e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 20 | 2.72e-01 | -0.142000 | 4.18e-01 |
| Late endosomal microautophagy | 29 | 1.86e-01 | -0.142000 | 3.21e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 35 | 1.47e-01 | -0.142000 | 2.69e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 3.13e-01 | -0.141000 | 4.61e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 69 | 4.33e-02 | -0.141000 | 1.16e-01 |
| Beta-catenin independent WNT signaling | 120 | 7.93e-03 | -0.140000 | 3.63e-02 |
| Resolution of Sister Chromatid Cohesion | 103 | 1.39e-02 | -0.140000 | 5.51e-02 |
| Pentose phosphate pathway | 14 | 3.65e-01 | -0.140000 | 5.13e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 75 | 3.64e-02 | -0.140000 | 1.03e-01 |
| Mitotic Spindle Checkpoint | 107 | 1.29e-02 | -0.139000 | 5.28e-02 |
| Metal ion SLC transporters | 17 | 3.22e-01 | 0.139000 | 4.70e-01 |
| Degradation of beta-catenin by the destruction complex | 77 | 3.57e-02 | -0.138000 | 1.02e-01 |
| Maturation of nucleoprotein | 10 | 4.49e-01 | -0.138000 | 5.93e-01 |
| Reproduction | 53 | 8.24e-02 | -0.138000 | 1.78e-01 |
| mRNA Splicing - Minor Pathway | 52 | 8.62e-02 | -0.138000 | 1.82e-01 |
| Intracellular signaling by second messengers | 251 | 1.81e-04 | -0.138000 | 2.67e-03 |
| Signaling by NOTCH3 | 41 | 1.28e-01 | -0.137000 | 2.48e-01 |
| Cell Cycle Checkpoints | 242 | 2.43e-04 | -0.137000 | 3.26e-03 |
| FCERI mediated MAPK activation | 23 | 2.57e-01 | -0.137000 | 4.00e-01 |
| Inflammasomes | 15 | 3.60e-01 | 0.137000 | 5.08e-01 |
| Cell Cycle, Mitotic | 466 | 5.01e-07 | -0.136000 | 1.76e-05 |
| CD28 co-stimulation | 25 | 2.38e-01 | -0.136000 | 3.79e-01 |
| G alpha (z) signalling events | 31 | 1.90e-01 | -0.136000 | 3.26e-01 |
| TP53 Regulates Metabolic Genes | 80 | 3.58e-02 | -0.136000 | 1.02e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 84 | 3.25e-02 | -0.135000 | 9.66e-02 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 3.83e-01 | -0.135000 | 5.26e-01 |
| Deubiquitination | 222 | 5.57e-04 | -0.135000 | 6.19e-03 |
| Cyclin A/B1/B2 associated events during G2/M transition | 23 | 2.64e-01 | -0.135000 | 4.07e-01 |
| DNA Damage Recognition in GG-NER | 37 | 1.57e-01 | -0.135000 | 2.82e-01 |
| Integration of energy metabolism | 76 | 4.27e-02 | -0.135000 | 1.15e-01 |
| Syndecan interactions | 19 | 3.11e-01 | -0.134000 | 4.60e-01 |
| RAF/MAP kinase cascade | 203 | 9.93e-04 | -0.134000 | 8.97e-03 |
| Dual incision in TC-NER | 62 | 7.06e-02 | -0.133000 | 1.60e-01 |
| Apoptosis | 148 | 5.38e-03 | -0.133000 | 2.82e-02 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 21 | 2.93e-01 | -0.133000 | 4.39e-01 |
| Signaling by NOTCH | 158 | 4.09e-03 | -0.133000 | 2.40e-02 |
| Frs2-mediated activation | 12 | 4.29e-01 | -0.132000 | 5.75e-01 |
| p75NTR signals via NF-kB | 15 | 3.77e-01 | 0.132000 | 5.22e-01 |
| ABC transporters in lipid homeostasis | 12 | 4.29e-01 | 0.132000 | 5.75e-01 |
| Glycogen synthesis | 15 | 3.77e-01 | 0.132000 | 5.22e-01 |
| Amino acids regulate mTORC1 | 48 | 1.15e-01 | -0.132000 | 2.27e-01 |
| HDR through Homologous Recombination (HRR) | 64 | 6.90e-02 | -0.132000 | 1.58e-01 |
| NRIF signals cell death from the nucleus | 15 | 3.79e-01 | -0.131000 | 5.23e-01 |
| Metabolism of steroid hormones | 15 | 3.81e-01 | -0.131000 | 5.25e-01 |
| Homology Directed Repair | 100 | 2.46e-02 | -0.130000 | 7.92e-02 |
| PI3K events in ERBB2 signaling | 11 | 4.55e-01 | -0.130000 | 5.97e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 4.78e-01 | -0.130000 | 6.18e-01 |
| Peptide hormone metabolism | 48 | 1.21e-01 | -0.129000 | 2.35e-01 |
| Activation of RAC1 | 11 | 4.58e-01 | 0.129000 | 5.99e-01 |
| Transferrin endocytosis and recycling | 23 | 2.83e-01 | -0.129000 | 4.27e-01 |
| G1/S Transition | 123 | 1.41e-02 | -0.128000 | 5.54e-02 |
| Formation of TC-NER Pre-Incision Complex | 50 | 1.18e-01 | -0.128000 | 2.30e-01 |
| RNA polymerase II transcribes snRNA genes | 75 | 5.60e-02 | -0.128000 | 1.39e-01 |
| Cleavage of the damaged purine | 11 | 4.64e-01 | -0.127000 | 6.04e-01 |
| Depurination | 11 | 4.64e-01 | -0.127000 | 6.04e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 11 | 4.64e-01 | -0.127000 | 6.04e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 94 | 3.34e-02 | -0.127000 | 9.85e-02 |
| Toll Like Receptor 3 (TLR3) Cascade | 85 | 4.39e-02 | -0.127000 | 1.17e-01 |
| Intraflagellar transport | 35 | 1.96e-01 | 0.126000 | 3.32e-01 |
| Programmed Cell Death | 158 | 6.44e-03 | -0.126000 | 3.21e-02 |
| Nicotinate metabolism | 22 | 3.08e-01 | 0.126000 | 4.57e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 273 | 3.72e-04 | -0.125000 | 4.65e-03 |
| Activation of Matrix Metalloproteinases | 18 | 3.58e-01 | -0.125000 | 5.06e-01 |
| Membrane Trafficking | 539 | 7.68e-07 | -0.125000 | 2.50e-05 |
| ER to Golgi Anterograde Transport | 122 | 1.77e-02 | -0.124000 | 6.45e-02 |
| Synthesis of bile acids and bile salts | 23 | 3.03e-01 | -0.124000 | 4.50e-01 |
| Generation of second messenger molecules | 11 | 4.77e-01 | -0.124000 | 6.17e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 2.75e-01 | 0.124000 | 4.21e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 32 | 2.26e-01 | -0.124000 | 3.65e-01 |
| Signaling by FGFR1 in disease | 30 | 2.43e-01 | -0.123000 | 3.84e-01 |
| Interconversion of nucleotide di- and triphosphates | 28 | 2.59e-01 | -0.123000 | 4.03e-01 |
| Alpha-protein kinase 1 signaling pathway | 11 | 4.80e-01 | 0.123000 | 6.19e-01 |
| DNA Repair | 274 | 4.72e-04 | -0.123000 | 5.68e-03 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 28 | 2.60e-01 | -0.123000 | 4.03e-01 |
| Nucleosome assembly | 28 | 2.60e-01 | -0.123000 | 4.03e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 17 | 3.80e-01 | -0.123000 | 5.24e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 17 | 3.80e-01 | -0.123000 | 5.24e-01 |
| Separation of Sister Chromatids | 162 | 7.23e-03 | -0.122000 | 3.42e-02 |
| Metabolism of lipids | 536 | 1.39e-06 | -0.122000 | 4.29e-05 |
| Signaling by Non-Receptor Tyrosine Kinases | 46 | 1.52e-01 | -0.122000 | 2.75e-01 |
| Signaling by PTK6 | 46 | 1.52e-01 | -0.122000 | 2.75e-01 |
| PIP3 activates AKT signaling | 220 | 1.88e-03 | -0.122000 | 1.43e-02 |
| MET promotes cell motility | 27 | 2.76e-01 | -0.121000 | 4.21e-01 |
| tRNA processing in the nucleus | 55 | 1.20e-01 | -0.121000 | 2.35e-01 |
| Mitochondrial biogenesis | 73 | 7.38e-02 | -0.121000 | 1.65e-01 |
| Mitochondrial translation initiation | 88 | 4.99e-02 | -0.121000 | 1.28e-01 |
| Metabolism of amino acids and derivatives | 278 | 5.35e-04 | 0.121000 | 6.04e-03 |
| Myogenesis | 21 | 3.38e-01 | -0.121000 | 4.86e-01 |
| Signalling to ERKs | 31 | 2.45e-01 | -0.121000 | 3.86e-01 |
| Mitochondrial translation termination | 88 | 5.10e-02 | -0.120000 | 1.29e-01 |
| M Phase | 330 | 1.96e-04 | -0.120000 | 2.77e-03 |
| Regulation of KIT signaling | 14 | 4.39e-01 | -0.120000 | 5.81e-01 |
| Elastic fibre formation | 34 | 2.29e-01 | 0.119000 | 3.68e-01 |
| HS-GAG degradation | 19 | 3.70e-01 | 0.119000 | 5.16e-01 |
| Endogenous sterols | 18 | 3.83e-01 | -0.119000 | 5.26e-01 |
| Interleukin-12 signaling | 36 | 2.20e-01 | -0.118000 | 3.58e-01 |
| Sphingolipid metabolism | 74 | 7.89e-02 | -0.118000 | 1.73e-01 |
| G2/M Checkpoints | 124 | 2.32e-02 | -0.118000 | 7.68e-02 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 3.50e-01 | -0.118000 | 4.98e-01 |
| tRNA modification in the nucleus and cytosol | 41 | 1.94e-01 | 0.117000 | 3.32e-01 |
| L1CAM interactions | 83 | 6.69e-02 | -0.116000 | 1.54e-01 |
| Amino acid transport across the plasma membrane | 18 | 3.94e-01 | -0.116000 | 5.39e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 88 | 6.07e-02 | -0.116000 | 1.46e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 42 | 1.95e-01 | -0.116000 | 3.32e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 40 | 2.06e-01 | 0.116000 | 3.42e-01 |
| Processing of Intronless Pre-mRNAs | 19 | 3.84e-01 | -0.115000 | 5.26e-01 |
| CD209 (DC-SIGN) signaling | 17 | 4.10e-01 | -0.115000 | 5.52e-01 |
| Prolonged ERK activation events | 14 | 4.55e-01 | -0.115000 | 5.97e-01 |
| MAPK1/MAPK3 signaling | 209 | 4.17e-03 | -0.115000 | 2.43e-02 |
| Signaling by Hippo | 19 | 3.85e-01 | -0.115000 | 5.28e-01 |
| Interleukin-4 and Interleukin-13 signaling | 74 | 8.72e-02 | 0.115000 | 1.83e-01 |
| Mitotic G1 phase and G1/S transition | 138 | 1.99e-02 | -0.115000 | 6.97e-02 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 90 | 6.04e-02 | -0.115000 | 1.46e-01 |
| Amplification of signal from the kinetochores | 90 | 6.04e-02 | -0.115000 | 1.46e-01 |
| Inositol phosphate metabolism | 38 | 2.22e-01 | -0.115000 | 3.60e-01 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 10 | 5.31e-01 | -0.114000 | 6.65e-01 |
| Signalling to RAS | 18 | 4.01e-01 | -0.114000 | 5.45e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 3.23e-01 | -0.114000 | 4.70e-01 |
| Synthesis of PC | 21 | 3.66e-01 | -0.114000 | 5.13e-01 |
| Extracellular matrix organization | 210 | 4.46e-03 | 0.114000 | 2.50e-02 |
| IRS-mediated signalling | 30 | 2.80e-01 | -0.114000 | 4.25e-01 |
| Signaling by PDGF | 46 | 1.82e-01 | 0.114000 | 3.16e-01 |
| tRNA processing | 122 | 3.03e-02 | -0.114000 | 9.28e-02 |
| Signal Transduction | 1645 | 4.04e-14 | -0.114000 | 3.09e-12 |
| Neddylation | 205 | 5.20e-03 | -0.113000 | 2.75e-02 |
| Mitochondrial iron-sulfur cluster biogenesis | 12 | 4.97e-01 | 0.113000 | 6.33e-01 |
| B-WICH complex positively regulates rRNA expression | 28 | 3.00e-01 | -0.113000 | 4.48e-01 |
| MTOR signalling | 40 | 2.16e-01 | -0.113000 | 3.56e-01 |
| Anchoring of the basal body to the plasma membrane | 90 | 6.43e-02 | 0.113000 | 1.50e-01 |
| Cell junction organization | 58 | 1.37e-01 | -0.113000 | 2.59e-01 |
| Switching of origins to a post-replicative state | 85 | 7.33e-02 | -0.112000 | 1.64e-01 |
| Regulation of insulin secretion | 54 | 1.53e-01 | -0.112000 | 2.77e-01 |
| MyD88 cascade initiated on plasma membrane | 76 | 9.12e-02 | -0.112000 | 1.89e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 76 | 9.12e-02 | -0.112000 | 1.89e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 76 | 9.12e-02 | -0.112000 | 1.89e-01 |
| Zinc transporters | 11 | 5.20e-01 | -0.112000 | 6.55e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 16 | 4.38e-01 | -0.112000 | 5.81e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 79 | 8.58e-02 | -0.112000 | 1.81e-01 |
| RIPK1-mediated regulated necrosis | 26 | 3.25e-01 | 0.111000 | 4.71e-01 |
| Regulated Necrosis | 26 | 3.25e-01 | 0.111000 | 4.71e-01 |
| Regulation of necroptotic cell death | 26 | 3.25e-01 | 0.111000 | 4.71e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 11 | 5.25e-01 | 0.111000 | 6.60e-01 |
| Leishmania infection | 144 | 2.20e-02 | -0.111000 | 7.51e-02 |
| Vesicle-mediated transport | 554 | 9.42e-06 | -0.111000 | 2.01e-04 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 3.49e-01 | -0.110000 | 4.98e-01 |
| Macroautophagy | 108 | 4.88e-02 | -0.110000 | 1.25e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 10 | 5.48e-01 | 0.110000 | 6.80e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 68 | 1.18e-01 | -0.110000 | 2.30e-01 |
| Synthesis of PA | 24 | 3.52e-01 | -0.110000 | 5.00e-01 |
| Autophagy | 120 | 3.84e-02 | -0.110000 | 1.08e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 84 | 8.34e-02 | -0.109000 | 1.78e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 84 | 8.34e-02 | -0.109000 | 1.78e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 84 | 8.34e-02 | -0.109000 | 1.78e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 84 | 8.34e-02 | -0.109000 | 1.78e-01 |
| Formation of the cornified envelope | 18 | 4.24e-01 | 0.109000 | 5.69e-01 |
| O-linked glycosylation of mucins | 33 | 2.80e-01 | 0.109000 | 4.25e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 10 | 5.54e-01 | -0.108000 | 6.84e-01 |
| Adaptive Immune System | 524 | 2.54e-05 | -0.108000 | 4.93e-04 |
| Nucleobase catabolism | 28 | 3.24e-01 | -0.108000 | 4.70e-01 |
| EML4 and NUDC in mitotic spindle formation | 94 | 7.13e-02 | -0.108000 | 1.61e-01 |
| WNT ligand biogenesis and trafficking | 14 | 4.85e-01 | -0.108000 | 6.24e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 20 | 4.11e-01 | -0.106000 | 5.53e-01 |
| C-type lectin receptors (CLRs) | 103 | 6.33e-02 | -0.106000 | 1.49e-01 |
| Mitochondrial translation | 94 | 7.62e-02 | -0.106000 | 1.69e-01 |
| VEGFR2 mediated cell proliferation | 18 | 4.39e-01 | -0.105000 | 5.81e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 13 | 5.12e-01 | 0.105000 | 6.47e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 13 | 5.12e-01 | 0.105000 | 6.47e-01 |
| Glycosaminoglycan metabolism | 97 | 7.44e-02 | 0.105000 | 1.65e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 5.66e-01 | 0.105000 | 6.95e-01 |
| Regulation of TP53 Activity | 145 | 2.94e-02 | -0.105000 | 9.11e-02 |
| ISG15 antiviral mechanism | 71 | 1.27e-01 | -0.105000 | 2.46e-01 |
| trans-Golgi Network Vesicle Budding | 70 | 1.30e-01 | -0.105000 | 2.49e-01 |
| Vitamin B5 (pantothenate) metabolism | 14 | 4.98e-01 | -0.105000 | 6.33e-01 |
| Class B/2 (Secretin family receptors) | 44 | 2.31e-01 | -0.104000 | 3.71e-01 |
| Downstream signaling of activated FGFR2 | 17 | 4.59e-01 | -0.104000 | 5.99e-01 |
| Signaling by NTRK3 (TRKC) | 15 | 4.87e-01 | -0.104000 | 6.24e-01 |
| mRNA decay by 3’ to 5’ exoribonuclease | 15 | 4.89e-01 | -0.103000 | 6.26e-01 |
| DNA Double-Strand Break Repair | 128 | 4.43e-02 | -0.103000 | 1.17e-01 |
| Mitochondrial translation elongation | 88 | 9.63e-02 | -0.103000 | 1.97e-01 |
| RNA Polymerase I Transcription | 43 | 2.45e-01 | -0.103000 | 3.86e-01 |
| Cyclin E associated events during G1/S transition | 76 | 1.23e-01 | -0.102000 | 2.39e-01 |
| Cilium Assembly | 165 | 2.34e-02 | 0.102000 | 7.71e-02 |
| Fc epsilon receptor (FCERI) signaling | 110 | 6.44e-02 | -0.102000 | 1.50e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 106 | 6.96e-02 | -0.102000 | 1.59e-01 |
| Synthesis of substrates in N-glycan biosythesis | 53 | 2.00e-01 | -0.102000 | 3.36e-01 |
| PI3K Cascade | 27 | 3.60e-01 | -0.102000 | 5.08e-01 |
| DAP12 interactions | 18 | 4.56e-01 | -0.102000 | 5.97e-01 |
| IL-6-type cytokine receptor ligand interactions | 13 | 5.31e-01 | 0.100000 | 6.65e-01 |
| Transcriptional regulation by RUNX3 | 87 | 1.07e-01 | -0.100000 | 2.14e-01 |
| Role of phospholipids in phagocytosis | 18 | 4.62e-01 | -0.100000 | 6.03e-01 |
| Mitochondrial protein import | 55 | 2.00e-01 | -0.099900 | 3.36e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 106 | 7.77e-02 | -0.099300 | 1.71e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 231 | 9.94e-03 | -0.098600 | 4.40e-02 |
| Signaling by Erythropoietin | 21 | 4.35e-01 | -0.098500 | 5.79e-01 |
| Metabolism of fat-soluble vitamins | 30 | 3.54e-01 | 0.097800 | 5.01e-01 |
| DNA Damage Bypass | 47 | 2.49e-01 | -0.097300 | 3.90e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 78 | 1.40e-01 | -0.096700 | 2.60e-01 |
| Signaling by PDGFR in disease | 17 | 4.90e-01 | 0.096700 | 6.26e-01 |
| SARS-CoV-1 Infection | 48 | 2.48e-01 | -0.096400 | 3.89e-01 |
| SLC-mediated transmembrane transport | 137 | 5.39e-02 | -0.095500 | 1.34e-01 |
| Signaling by NOTCH4 | 76 | 1.52e-01 | -0.095200 | 2.75e-01 |
| Cell recruitment (pro-inflammatory response) | 19 | 4.73e-01 | 0.095100 | 6.13e-01 |
| Purinergic signaling in leishmaniasis infection | 19 | 4.73e-01 | 0.095100 | 6.13e-01 |
| SLC transporter disorders | 62 | 1.97e-01 | -0.094900 | 3.32e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 34 | 3.39e-01 | -0.094700 | 4.87e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 6.04e-01 | -0.094700 | 7.26e-01 |
| RNA Polymerase III Chain Elongation | 17 | 5.01e-01 | -0.094300 | 6.37e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 17 | 5.01e-01 | 0.094200 | 6.37e-01 |
| APC/C-mediated degradation of cell cycle proteins | 82 | 1.41e-01 | -0.094200 | 2.60e-01 |
| Regulation of mitotic cell cycle | 82 | 1.41e-01 | -0.094200 | 2.60e-01 |
| G alpha (s) signalling events | 73 | 1.66e-01 | -0.093800 | 2.93e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 172 | 3.40e-02 | -0.093800 | 9.96e-02 |
| Ovarian tumor domain proteases | 33 | 3.52e-01 | -0.093600 | 5.00e-01 |
| Translesion synthesis by REV1 | 16 | 5.17e-01 | -0.093500 | 6.53e-01 |
| Potassium Channels | 45 | 2.78e-01 | 0.093400 | 4.23e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 5.76e-01 | -0.093400 | 7.03e-01 |
| Signaling by NTRK2 (TRKB) | 22 | 4.50e-01 | -0.093000 | 5.93e-01 |
| DNA Replication Pre-Initiation | 79 | 1.55e-01 | -0.092600 | 2.80e-01 |
| RNA Polymerase I Transcription Initiation | 38 | 3.24e-01 | -0.092500 | 4.70e-01 |
| Transmission across Chemical Synapses | 147 | 5.37e-02 | -0.092300 | 1.34e-01 |
| Innate Immune System | 661 | 5.88e-05 | -0.092100 | 1.02e-03 |
| Nonhomologous End-Joining (NHEJ) | 32 | 3.69e-01 | -0.091800 | 5.16e-01 |
| Golgi Associated Vesicle Biogenesis | 55 | 2.40e-01 | -0.091600 | 3.81e-01 |
| RNA Polymerase III Transcription Termination | 22 | 4.58e-01 | -0.091300 | 5.99e-01 |
| PTEN Regulation | 130 | 7.30e-02 | -0.091200 | 1.64e-01 |
| Class I MHC mediated antigen processing & presentation | 314 | 5.64e-03 | -0.091100 | 2.92e-02 |
| Diseases of carbohydrate metabolism | 28 | 4.07e-01 | -0.090600 | 5.49e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 23 | 4.53e-01 | -0.090300 | 5.96e-01 |
| O-linked glycosylation | 73 | 1.84e-01 | 0.090100 | 3.18e-01 |
| CLEC7A (Dectin-1) signaling | 89 | 1.43e-01 | -0.089800 | 2.64e-01 |
| Cell-Cell communication | 84 | 1.59e-01 | -0.089000 | 2.83e-01 |
| Signaling by Receptor Tyrosine Kinases | 401 | 2.31e-03 | -0.089000 | 1.65e-02 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 3.70e-01 | -0.088900 | 5.16e-01 |
| Josephin domain DUBs | 10 | 6.29e-01 | -0.088200 | 7.46e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 67 | 2.13e-01 | -0.088100 | 3.52e-01 |
| RHOBTB GTPase Cycle | 17 | 5.29e-01 | -0.088100 | 6.64e-01 |
| Degradation of GLI2 by the proteasome | 53 | 2.68e-01 | -0.087900 | 4.13e-01 |
| Assembly and cell surface presentation of NMDA receptors | 15 | 5.57e-01 | 0.087600 | 6.86e-01 |
| RNA Polymerase I Promoter Clearance | 42 | 3.28e-01 | -0.087200 | 4.74e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 72 | 2.01e-01 | -0.087200 | 3.37e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 68 | 2.15e-01 | -0.087000 | 3.55e-01 |
| mRNA Splicing - Major Pathway | 171 | 5.09e-02 | -0.086700 | 1.29e-01 |
| IRAK2 mediated activation of TAK1 complex | 10 | 6.36e-01 | -0.086400 | 7.51e-01 |
| Defective B3GAT3 causes JDSSDHD | 16 | 5.51e-01 | 0.086200 | 6.82e-01 |
| GLI3 is processed to GLI3R by the proteasome | 53 | 2.81e-01 | -0.085700 | 4.25e-01 |
| Translesion Synthesis by POLH | 19 | 5.19e-01 | 0.085500 | 6.54e-01 |
| GPCR ligand binding | 143 | 7.89e-02 | 0.085200 | 1.73e-01 |
| Signaling by FLT3 ITD and TKD mutants | 15 | 5.68e-01 | -0.085200 | 6.97e-01 |
| Ub-specific processing proteases | 153 | 6.94e-02 | -0.085200 | 1.59e-01 |
| FLT3 signaling in disease | 26 | 4.54e-01 | -0.084900 | 5.96e-01 |
| FCERI mediated Ca+2 mobilization | 22 | 4.94e-01 | -0.084200 | 6.31e-01 |
| Heme biosynthesis | 12 | 6.15e-01 | -0.083800 | 7.35e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 75 | 2.11e-01 | -0.083700 | 3.49e-01 |
| TCR signaling | 85 | 1.83e-01 | -0.083700 | 3.17e-01 |
| Glycogen storage diseases | 14 | 5.88e-01 | -0.083600 | 7.11e-01 |
| Condensation of Prometaphase Chromosomes | 10 | 6.47e-01 | -0.083600 | 7.60e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 18 | 5.42e-01 | -0.083000 | 6.74e-01 |
| Antiviral mechanism by IFN-stimulated genes | 79 | 2.05e-01 | -0.082600 | 3.42e-01 |
| mTORC1-mediated signalling | 24 | 4.84e-01 | -0.082600 | 6.23e-01 |
| Disease | 1155 | 3.41e-06 | -0.081900 | 9.04e-05 |
| p75NTR recruits signalling complexes | 12 | 6.25e-01 | 0.081600 | 7.42e-01 |
| Pexophagy | 11 | 6.40e-01 | 0.081600 | 7.55e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 26 | 4.73e-01 | -0.081300 | 6.13e-01 |
| Protein methylation | 16 | 5.75e-01 | 0.080900 | 7.03e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 62 | 2.72e-01 | -0.080600 | 4.18e-01 |
| Activation of ATR in response to replication stress | 37 | 3.98e-01 | -0.080300 | 5.42e-01 |
| Regulation of RAS by GAPs | 57 | 3.00e-01 | -0.079400 | 4.48e-01 |
| Neutrophil degranulation | 323 | 1.45e-02 | -0.079300 | 5.60e-02 |
| Synthesis of very long-chain fatty acyl-CoAs | 16 | 5.85e-01 | -0.078900 | 7.10e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 10 | 6.66e-01 | -0.078900 | 7.74e-01 |
| Depolymerisation of the Nuclear Lamina | 14 | 6.09e-01 | -0.078900 | 7.31e-01 |
| Metabolism of cofactors | 17 | 5.74e-01 | -0.078700 | 7.03e-01 |
| Centrosome maturation | 75 | 2.39e-01 | 0.078700 | 3.79e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 75 | 2.39e-01 | 0.078700 | 3.79e-01 |
| Mucopolysaccharidoses | 10 | 6.69e-01 | -0.078200 | 7.76e-01 |
| IGF1R signaling cascade | 33 | 4.39e-01 | -0.077900 | 5.81e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 33 | 4.39e-01 | -0.077900 | 5.81e-01 |
| FGFR1 mutant receptor activation | 24 | 5.11e-01 | -0.077500 | 6.47e-01 |
| Serotonin Neurotransmitter Release Cycle | 11 | 6.57e-01 | -0.077400 | 7.68e-01 |
| CS/DS degradation | 10 | 6.72e-01 | -0.077300 | 7.80e-01 |
| Mitophagy | 26 | 4.96e-01 | -0.077200 | 6.32e-01 |
| Arachidonic acid metabolism | 22 | 5.34e-01 | 0.076500 | 6.67e-01 |
| XBP1(S) activates chaperone genes | 45 | 3.76e-01 | -0.076300 | 5.22e-01 |
| Post-translational protein modification | 1115 | 2.15e-05 | -0.076200 | 4.29e-04 |
| Regulation of ornithine decarboxylase (ODC) | 45 | 3.78e-01 | -0.076100 | 5.22e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 67 | 2.84e-01 | -0.075700 | 4.28e-01 |
| GPCR downstream signalling | 340 | 1.81e-02 | -0.074800 | 6.53e-02 |
| Immune System | 1297 | 7.68e-06 | -0.074800 | 1.70e-04 |
| Signaling by NTRK1 (TRKA) | 105 | 1.91e-01 | -0.074000 | 3.27e-01 |
| Neurexins and neuroligins | 38 | 4.36e-01 | -0.073100 | 5.79e-01 |
| G alpha (q) signalling events | 105 | 1.97e-01 | -0.073000 | 3.32e-01 |
| Signaling by GPCR | 373 | 1.60e-02 | -0.072900 | 5.88e-02 |
| Dual Incision in GG-NER | 40 | 4.33e-01 | -0.071700 | 5.78e-01 |
| UCH proteinases | 78 | 2.75e-01 | -0.071600 | 4.21e-01 |
| PI-3K cascade:FGFR1 | 12 | 6.69e-01 | -0.071400 | 7.76e-01 |
| Degradation of GLI1 by the proteasome | 52 | 3.75e-01 | -0.071200 | 5.21e-01 |
| Activation of SMO | 16 | 6.23e-01 | 0.071000 | 7.41e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 10 | 6.98e-01 | -0.070900 | 8.01e-01 |
| Regulation of signaling by CBL | 14 | 6.47e-01 | -0.070600 | 7.60e-01 |
| Translesion synthesis by POLI | 17 | 6.15e-01 | -0.070400 | 7.35e-01 |
| DNA Double Strand Break Response | 42 | 4.32e-01 | -0.070100 | 5.77e-01 |
| Keratan sulfate/keratin metabolism | 26 | 5.36e-01 | 0.070100 | 6.69e-01 |
| Glutathione synthesis and recycling | 10 | 7.02e-01 | 0.070000 | 8.04e-01 |
| Metabolism | 1546 | 6.26e-06 | -0.069800 | 1.48e-04 |
| Erythropoietin activates RAS | 11 | 6.89e-01 | -0.069700 | 7.95e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 54 | 3.76e-01 | -0.069600 | 5.22e-01 |
| Synthesis of PE | 10 | 7.03e-01 | -0.069500 | 8.05e-01 |
| Signaling by NTRKs | 122 | 1.86e-01 | -0.069300 | 3.21e-01 |
| Downstream TCR signaling | 71 | 3.13e-01 | -0.069300 | 4.61e-01 |
| Diseases associated with the TLR signaling cascade | 18 | 6.11e-01 | 0.069300 | 7.31e-01 |
| Diseases of Immune System | 18 | 6.11e-01 | 0.069300 | 7.31e-01 |
| NF-kB is activated and signals survival | 12 | 6.79e-01 | 0.068900 | 7.85e-01 |
| NCAM signaling for neurite out-growth | 44 | 4.29e-01 | -0.068900 | 5.75e-01 |
| mRNA Splicing | 182 | 1.10e-01 | -0.068800 | 2.19e-01 |
| IRS-related events triggered by IGF1R | 32 | 5.05e-01 | -0.068100 | 6.40e-01 |
| Folding of actin by CCT/TriC | 10 | 7.10e-01 | -0.068000 | 8.09e-01 |
| Transcriptional regulation by RUNX2 | 107 | 2.27e-01 | -0.067700 | 3.66e-01 |
| PCP/CE pathway | 82 | 2.90e-01 | -0.067600 | 4.36e-01 |
| Killing mechanisms | 10 | 7.14e-01 | -0.067000 | 8.11e-01 |
| WNT5:FZD7-mediated leishmania damping | 10 | 7.14e-01 | -0.067000 | 8.11e-01 |
| TRP channels | 15 | 6.54e-01 | -0.066800 | 7.66e-01 |
| Presynaptic depolarization and calcium channel opening | 11 | 7.03e-01 | 0.066500 | 8.05e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 5.43e-01 | -0.066400 | 6.75e-01 |
| GABA synthesis, release, reuptake and degradation | 11 | 7.05e-01 | -0.066000 | 8.05e-01 |
| Selective autophagy | 56 | 3.99e-01 | -0.065100 | 5.43e-01 |
| PI-3K cascade:FGFR4 | 10 | 7.24e-01 | -0.064500 | 8.19e-01 |
| TNFR1-induced proapoptotic signaling | 12 | 6.99e-01 | 0.064400 | 8.03e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 74 | 3.42e-01 | -0.063900 | 4.89e-01 |
| Leishmania parasite growth and survival | 74 | 3.42e-01 | -0.063900 | 4.89e-01 |
| Phase 0 - rapid depolarisation | 22 | 6.05e-01 | -0.063700 | 7.26e-01 |
| Metabolism of porphyrins | 17 | 6.50e-01 | -0.063500 | 7.63e-01 |
| Recruitment of NuMA to mitotic centrosomes | 74 | 3.46e-01 | 0.063400 | 4.94e-01 |
| ER Quality Control Compartment (ERQC) | 19 | 6.33e-01 | -0.063300 | 7.49e-01 |
| SARS-CoV-2 Infection | 65 | 3.78e-01 | -0.063300 | 5.22e-01 |
| TNFR1-induced NFkappaB signaling pathway | 25 | 5.85e-01 | 0.063100 | 7.10e-01 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 68 | 3.71e-01 | -0.062800 | 5.17e-01 |
| VLDLR internalisation and degradation | 11 | 7.19e-01 | -0.062800 | 8.15e-01 |
| Plasma lipoprotein clearance | 24 | 6.02e-01 | -0.061500 | 7.24e-01 |
| Signaling by Retinoic Acid | 30 | 5.62e-01 | -0.061200 | 6.92e-01 |
| Signaling by the B Cell Receptor (BCR) | 91 | 3.15e-01 | -0.061000 | 4.63e-01 |
| Protein localization | 141 | 2.13e-01 | -0.060800 | 3.52e-01 |
| RUNX2 regulates bone development | 27 | 5.88e-01 | 0.060300 | 7.11e-01 |
| Stimuli-sensing channels | 60 | 4.23e-01 | -0.059800 | 5.69e-01 |
| Cargo trafficking to the periciliary membrane | 43 | 5.05e-01 | 0.058800 | 6.40e-01 |
| Mitochondrial tRNA aminoacylation | 17 | 6.76e-01 | -0.058500 | 7.82e-01 |
| Transport of small molecules | 450 | 3.42e-02 | -0.058500 | 1.00e-01 |
| Regulation of TNFR1 signaling | 33 | 5.66e-01 | 0.057800 | 6.95e-01 |
| Transcriptional regulation by RUNX1 | 149 | 2.25e-01 | -0.057600 | 3.65e-01 |
| Toll-like Receptor Cascades | 120 | 2.76e-01 | -0.057600 | 4.21e-01 |
| Defects in vitamin and cofactor metabolism | 19 | 6.64e-01 | -0.057500 | 7.73e-01 |
| FCERI mediated NF-kB activation | 69 | 4.09e-01 | -0.057500 | 5.52e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 70 | 4.10e-01 | -0.057000 | 5.52e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 71 | 4.07e-01 | -0.057000 | 5.49e-01 |
| mRNA 3’-end processing | 54 | 4.70e-01 | -0.056900 | 6.10e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 60 | 4.48e-01 | -0.056700 | 5.91e-01 |
| COPII-mediated vesicle transport | 60 | 4.50e-01 | -0.056400 | 5.93e-01 |
| Downstream signal transduction | 26 | 6.21e-01 | 0.056100 | 7.39e-01 |
| Laminin interactions | 23 | 6.42e-01 | 0.056100 | 7.56e-01 |
| Metabolism of polyamines | 52 | 4.85e-01 | -0.056000 | 6.23e-01 |
| Regulation of TP53 Degradation | 33 | 5.80e-01 | -0.055700 | 7.08e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 41 | 5.40e-01 | -0.055300 | 6.72e-01 |
| Ion channel transport | 108 | 3.22e-01 | -0.055200 | 4.70e-01 |
| Diseases associated with O-glycosylation of proteins | 42 | 5.37e-01 | 0.055100 | 6.69e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 30 | 6.02e-01 | -0.055100 | 7.24e-01 |
| Cytosolic sensors of pathogen-associated DNA | 53 | 4.89e-01 | 0.055000 | 6.26e-01 |
| Muscle contraction | 104 | 3.35e-01 | -0.054700 | 4.82e-01 |
| Cell-cell junction organization | 34 | 5.82e-01 | 0.054600 | 7.08e-01 |
| DAP12 signaling | 17 | 6.97e-01 | -0.054500 | 8.01e-01 |
| Non-integrin membrane-ECM interactions | 37 | 5.71e-01 | -0.053800 | 7.00e-01 |
| AURKA Activation by TPX2 | 66 | 4.51e-01 | 0.053700 | 5.93e-01 |
| Interferon Signaling | 145 | 2.66e-01 | 0.053600 | 4.10e-01 |
| Nervous system development | 475 | 4.65e-02 | 0.053500 | 1.21e-01 |
| Telomere Extension By Telomerase | 23 | 6.60e-01 | -0.053100 | 7.69e-01 |
| Antigen processing-Cross presentation | 73 | 4.34e-01 | 0.053000 | 5.78e-01 |
| Interleukin-37 signaling | 17 | 7.11e-01 | -0.052000 | 8.10e-01 |
| Protein-protein interactions at synapses | 63 | 4.81e-01 | 0.051400 | 6.20e-01 |
| Assembly of the pre-replicative complex | 62 | 4.87e-01 | -0.051100 | 6.24e-01 |
| Hedgehog ligand biogenesis | 57 | 5.06e-01 | 0.051000 | 6.41e-01 |
| Intra-Golgi traffic | 40 | 5.77e-01 | 0.051000 | 7.04e-01 |
| TRAF6 mediated IRF7 activation | 14 | 7.41e-01 | 0.051000 | 8.36e-01 |
| Class I peroxisomal membrane protein import | 20 | 6.96e-01 | 0.050400 | 8.01e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 23 | 6.76e-01 | 0.050400 | 7.82e-01 |
| Trafficking of AMPA receptors | 23 | 6.76e-01 | 0.050400 | 7.82e-01 |
| Nuclear Receptor transcription pathway | 40 | 5.84e-01 | -0.050000 | 7.10e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 49 | 5.50e-01 | -0.049400 | 6.82e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 55 | 5.27e-01 | -0.049400 | 6.62e-01 |
| Sialic acid metabolism | 27 | 6.58e-01 | 0.049200 | 7.69e-01 |
| Regulation of TP53 Activity through Phosphorylation | 86 | 4.31e-01 | -0.049100 | 5.77e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 12 | 7.69e-01 | -0.049000 | 8.58e-01 |
| Metabolism of proteins | 1578 | 1.41e-03 | -0.048900 | 1.16e-02 |
| Disorders of transmembrane transporters | 122 | 3.52e-01 | -0.048800 | 5.00e-01 |
| Signaling by FLT3 fusion proteins | 18 | 7.22e-01 | -0.048400 | 8.18e-01 |
| rRNA modification in the nucleus and cytosol | 59 | 5.20e-01 | 0.048400 | 6.55e-01 |
| IRE1alpha activates chaperones | 47 | 5.67e-01 | -0.048300 | 6.96e-01 |
| G alpha (i) signalling events | 175 | 2.76e-01 | -0.047800 | 4.21e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 31 | 6.47e-01 | 0.047600 | 7.60e-01 |
| Degradation of the extracellular matrix | 73 | 4.84e-01 | 0.047400 | 6.23e-01 |
| Axon guidance | 455 | 8.55e-02 | 0.047200 | 1.81e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 12 | 7.79e-01 | -0.046800 | 8.65e-01 |
| Metabolism of carbohydrates | 235 | 2.18e-01 | -0.046800 | 3.57e-01 |
| Iron uptake and transport | 47 | 5.85e-01 | -0.046100 | 7.10e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 44 | 5.98e-01 | 0.046000 | 7.20e-01 |
| Negative regulation of NOTCH4 signaling | 49 | 5.82e-01 | -0.045500 | 7.08e-01 |
| Elevation of cytosolic Ca2+ levels | 10 | 8.05e-01 | 0.045100 | 8.76e-01 |
| TRAF3-dependent IRF activation pathway | 12 | 7.88e-01 | -0.044900 | 8.68e-01 |
| Orc1 removal from chromatin | 65 | 5.33e-01 | -0.044800 | 6.67e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 13 | 7.81e-01 | -0.044600 | 8.65e-01 |
| Translesion synthesis by POLK | 17 | 7.50e-01 | -0.044600 | 8.45e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 7.92e-01 | 0.044100 | 8.69e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 7.92e-01 | 0.044100 | 8.69e-01 |
| G1/S DNA Damage Checkpoints | 60 | 5.56e-01 | -0.043900 | 6.86e-01 |
| Degradation of AXIN | 49 | 5.97e-01 | -0.043700 | 7.19e-01 |
| Glycosphingolipid metabolism | 36 | 6.53e-01 | -0.043300 | 7.65e-01 |
| Signaling by Activin | 12 | 7.96e-01 | -0.043200 | 8.70e-01 |
| Infectious disease | 619 | 6.96e-02 | -0.043000 | 1.59e-01 |
| Translation of structural proteins | 28 | 6.96e-01 | -0.042700 | 8.01e-01 |
| Regulation of RUNX2 expression and activity | 65 | 5.52e-01 | -0.042700 | 6.83e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 49 | 6.16e-01 | -0.041400 | 7.35e-01 |
| Glutamate Neurotransmitter Release Cycle | 16 | 7.75e-01 | -0.041400 | 8.61e-01 |
| RNA Polymerase I Transcription Termination | 25 | 7.21e-01 | -0.041300 | 8.17e-01 |
| Regulation of PTEN mRNA translation | 13 | 7.97e-01 | -0.041200 | 8.70e-01 |
| Metabolic disorders of biological oxidation enzymes | 21 | 7.47e-01 | -0.040700 | 8.42e-01 |
| Platelet calcium homeostasis | 18 | 7.65e-01 | 0.040700 | 8.55e-01 |
| Processing of Capped Intronless Pre-mRNA | 28 | 7.12e-01 | -0.040300 | 8.10e-01 |
| Asparagine N-linked glycosylation | 255 | 2.76e-01 | -0.039700 | 4.21e-01 |
| Phase II - Conjugation of compounds | 52 | 6.22e-01 | 0.039600 | 7.40e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 15 | 7.92e-01 | 0.039400 | 8.69e-01 |
| Loss of Nlp from mitotic centrosomes | 63 | 5.90e-01 | 0.039300 | 7.12e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 63 | 5.90e-01 | 0.039300 | 7.12e-01 |
| Hedgehog ‘on’ state | 77 | 5.52e-01 | -0.039200 | 6.83e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 7.64e-01 | -0.038700 | 8.55e-01 |
| Regulation of RUNX3 expression and activity | 50 | 6.36e-01 | -0.038700 | 7.51e-01 |
| IRAK1 recruits IKK complex | 10 | 8.33e-01 | -0.038500 | 8.95e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 8.33e-01 | -0.038500 | 8.95e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 46 | 6.53e-01 | -0.038400 | 7.65e-01 |
| Signaling by SCF-KIT | 33 | 7.06e-01 | 0.037900 | 8.06e-01 |
| NGF-stimulated transcription | 34 | 7.04e-01 | -0.037600 | 8.05e-01 |
| Termination of translesion DNA synthesis | 31 | 7.17e-01 | -0.037600 | 8.14e-01 |
| Nephrin family interactions | 18 | 7.83e-01 | 0.037400 | 8.67e-01 |
| Transport to the Golgi and subsequent modification | 149 | 4.35e-01 | -0.037100 | 5.79e-01 |
| RUNX2 regulates osteoblast differentiation | 21 | 7.70e-01 | 0.036900 | 8.58e-01 |
| Mitotic Prometaphase | 178 | 3.97e-01 | -0.036900 | 5.41e-01 |
| ER-Phagosome pathway | 64 | 6.11e-01 | 0.036800 | 7.31e-01 |
| Defects in cobalamin (B12) metabolism | 11 | 8.33e-01 | 0.036600 | 8.95e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 49 | 6.60e-01 | -0.036400 | 7.69e-01 |
| Platelet sensitization by LDL | 14 | 8.15e-01 | -0.036200 | 8.86e-01 |
| Transcriptional regulation of granulopoiesis | 28 | 7.41e-01 | -0.036100 | 8.36e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 10 | 8.44e-01 | -0.035900 | 9.02e-01 |
| RNA Polymerase I Promoter Escape | 25 | 7.59e-01 | 0.035400 | 8.52e-01 |
| Interleukin-12 family signaling | 43 | 6.89e-01 | -0.035300 | 7.95e-01 |
| Diseases of glycosylation | 107 | 5.33e-01 | 0.034900 | 6.67e-01 |
| Glutathione conjugation | 24 | 7.70e-01 | -0.034600 | 8.58e-01 |
| Unfolded Protein Response (UPR) | 85 | 5.88e-01 | 0.034000 | 7.11e-01 |
| Organelle biogenesis and maintenance | 238 | 3.70e-01 | 0.033800 | 5.16e-01 |
| Cell surface interactions at the vascular wall | 72 | 6.25e-01 | -0.033300 | 7.42e-01 |
| PINK1-PRKN Mediated Mitophagy | 20 | 7.98e-01 | 0.033000 | 8.71e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 8.21e-01 | 0.032700 | 8.87e-01 |
| tRNA Aminoacylation | 23 | 7.87e-01 | -0.032500 | 8.68e-01 |
| WNT5A-dependent internalization of FZD4 | 14 | 8.35e-01 | -0.032100 | 8.95e-01 |
| RNA Polymerase II Transcription Termination | 63 | 6.62e-01 | -0.031900 | 7.71e-01 |
| Regulation of TP53 Activity through Methylation | 18 | 8.17e-01 | -0.031600 | 8.86e-01 |
| Diseases associated with N-glycosylation of proteins | 17 | 8.24e-01 | 0.031200 | 8.88e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 8.58e-01 | 0.031200 | 9.11e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 33 | 7.58e-01 | 0.031100 | 8.51e-01 |
| Metabolism of folate and pterines | 15 | 8.36e-01 | 0.030900 | 8.95e-01 |
| Methylation | 11 | 8.60e-01 | 0.030700 | 9.13e-01 |
| Interleukin receptor SHC signaling | 14 | 8.45e-01 | -0.030100 | 9.02e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 81 | 6.41e-01 | 0.030000 | 7.56e-01 |
| MET activates PTK2 signaling | 17 | 8.36e-01 | -0.029100 | 8.95e-01 |
| Nuclear signaling by ERBB4 | 25 | 8.02e-01 | 0.028900 | 8.74e-01 |
| Blood group systems biosynthesis | 11 | 8.68e-01 | -0.028900 | 9.18e-01 |
| Other interleukin signaling | 15 | 8.47e-01 | -0.028800 | 9.03e-01 |
| Neurotransmitter release cycle | 29 | 7.93e-01 | -0.028200 | 8.69e-01 |
| Regulation of TP53 Expression and Degradation | 34 | 7.83e-01 | -0.027300 | 8.67e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 7.73e-01 | -0.027100 | 8.60e-01 |
| Interleukin-1 family signaling | 109 | 6.31e-01 | -0.026700 | 7.47e-01 |
| Metabolism of steroids | 111 | 6.29e-01 | -0.026500 | 7.46e-01 |
| Tie2 Signaling | 12 | 8.76e-01 | -0.026100 | 9.23e-01 |
| TNF signaling | 41 | 7.73e-01 | 0.026000 | 8.60e-01 |
| Condensation of Prophase Chromosomes | 14 | 8.67e-01 | -0.025900 | 9.17e-01 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 8.82e-01 | -0.025800 | 9.28e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 8.18e-01 | -0.025600 | 8.86e-01 |
| Fanconi Anemia Pathway | 37 | 7.95e-01 | -0.024600 | 8.70e-01 |
| Calnexin/calreticulin cycle | 24 | 8.36e-01 | 0.024400 | 8.95e-01 |
| Cytochrome P450 - arranged by substrate type | 30 | 8.21e-01 | -0.023800 | 8.87e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 44 | 7.85e-01 | 0.023800 | 8.67e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 46 | 7.84e-01 | 0.023400 | 8.67e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 59 | 7.58e-01 | -0.023200 | 8.51e-01 |
| Peroxisomal protein import | 54 | 7.70e-01 | -0.023000 | 8.58e-01 |
| Stabilization of p53 | 50 | 7.80e-01 | 0.022800 | 8.65e-01 |
| Gene expression (Transcription) | 1223 | 1.93e-01 | -0.022300 | 3.31e-01 |
| Retrograde transport at the Trans-Golgi-Network | 47 | 7.93e-01 | -0.022100 | 8.69e-01 |
| Ion transport by P-type ATPases | 32 | 8.32e-01 | 0.021700 | 8.95e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 28 | 8.45e-01 | -0.021400 | 9.02e-01 |
| Netrin-1 signaling | 40 | 8.18e-01 | -0.021000 | 8.86e-01 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 40 | 8.19e-01 | 0.020900 | 8.86e-01 |
| p53-Dependent G1 DNA Damage Response | 58 | 7.89e-01 | -0.020300 | 8.68e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 58 | 7.89e-01 | -0.020300 | 8.68e-01 |
| Developmental Biology | 708 | 3.62e-01 | -0.020200 | 5.10e-01 |
| SARS-CoV Infections | 126 | 6.97e-01 | -0.020100 | 8.01e-01 |
| NOD1/2 Signaling Pathway | 29 | 8.54e-01 | -0.019800 | 9.08e-01 |
| ABC-family proteins mediated transport | 80 | 7.61e-01 | 0.019700 | 8.52e-01 |
| Ion homeostasis | 32 | 8.47e-01 | -0.019700 | 9.03e-01 |
| Fatty acyl-CoA biosynthesis | 25 | 8.65e-01 | -0.019600 | 9.16e-01 |
| Signaling by Interleukins | 315 | 5.55e-01 | -0.019400 | 6.85e-01 |
| Activation of NF-kappaB in B cells | 60 | 7.96e-01 | -0.019300 | 8.70e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 48 | 8.19e-01 | -0.019100 | 8.86e-01 |
| Synaptic adhesion-like molecules | 14 | 9.02e-01 | -0.018900 | 9.46e-01 |
| Lysine catabolism | 11 | 9.16e-01 | 0.018300 | 9.56e-01 |
| Defective CFTR causes cystic fibrosis | 52 | 8.22e-01 | -0.018000 | 8.87e-01 |
| Peroxisomal lipid metabolism | 25 | 8.79e-01 | 0.017500 | 9.26e-01 |
| TRAF6 mediated NF-kB activation | 20 | 8.94e-01 | -0.017300 | 9.39e-01 |
| Biological oxidations | 105 | 7.63e-01 | 0.017100 | 8.54e-01 |
| Incretin synthesis, secretion, and inactivation | 13 | 9.15e-01 | -0.017000 | 9.56e-01 |
| Interleukin-1 signaling | 89 | 7.87e-01 | -0.016600 | 8.68e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 43 | 8.52e-01 | 0.016500 | 9.07e-01 |
| Activation of gene expression by SREBF (SREBP) | 42 | 8.62e-01 | -0.015500 | 9.13e-01 |
| Mitotic G2-G2/M phases | 170 | 7.30e-01 | -0.015400 | 8.25e-01 |
| Regulation of Apoptosis | 47 | 8.62e-01 | 0.014700 | 9.13e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 14 | 9.25e-01 | -0.014500 | 9.59e-01 |
| Hedgehog ‘off’ state | 87 | 8.17e-01 | -0.014300 | 8.86e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 57 | 8.56e-01 | -0.013900 | 9.10e-01 |
| Signaling by ERBB4 | 43 | 8.74e-01 | 0.013900 | 9.23e-01 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 9.32e-01 | -0.013600 | 9.63e-01 |
| Visual phototransduction | 50 | 8.75e-01 | 0.012900 | 9.23e-01 |
| PI-3K cascade:FGFR2 | 11 | 9.43e-01 | 0.012400 | 9.71e-01 |
| Metabolism of water-soluble vitamins and cofactors | 95 | 8.37e-01 | -0.012200 | 8.95e-01 |
| Keratan sulfate biosynthesis | 21 | 9.24e-01 | 0.012100 | 9.59e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 9.45e-01 | 0.011500 | 9.72e-01 |
| Potential therapeutics for SARS | 62 | 8.76e-01 | 0.011500 | 9.23e-01 |
| Keratinization | 27 | 9.21e-01 | -0.011000 | 9.59e-01 |
| Cargo concentration in the ER | 26 | 9.23e-01 | -0.010900 | 9.59e-01 |
| Asymmetric localization of PCP proteins | 57 | 8.98e-01 | 0.009770 | 9.43e-01 |
| NIK–>noncanonical NF-kB signaling | 53 | 9.04e-01 | 0.009590 | 9.46e-01 |
| Cellular response to hypoxia | 64 | 8.97e-01 | -0.009390 | 9.42e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 20 | 9.42e-01 | -0.009380 | 9.70e-01 |
| Regulation of PTEN stability and activity | 60 | 9.04e-01 | -0.009000 | 9.46e-01 |
| Integrin cell surface interactions | 50 | 9.13e-01 | 0.008940 | 9.54e-01 |
| Glycogen breakdown (glycogenolysis) | 14 | 9.55e-01 | -0.008790 | 9.75e-01 |
| Cytokine Signaling in Immune system | 479 | 7.49e-01 | -0.008560 | 8.44e-01 |
| Cellular responses to stress | 458 | 7.55e-01 | 0.008550 | 8.49e-01 |
| Vpu mediated degradation of CD4 | 45 | 9.26e-01 | -0.008000 | 9.59e-01 |
| Degradation of DVL | 51 | 9.23e-01 | -0.007810 | 9.59e-01 |
| Dopamine Neurotransmitter Release Cycle | 15 | 9.58e-01 | 0.007760 | 9.77e-01 |
| Glycogen metabolism | 25 | 9.47e-01 | 0.007660 | 9.72e-01 |
| Adherens junctions interactions | 18 | 9.57e-01 | 0.007420 | 9.75e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 18 | 9.57e-01 | 0.007410 | 9.75e-01 |
| Transcriptional regulation of pluripotent stem cells | 19 | 9.56e-01 | -0.007370 | 9.75e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 53 | 9.26e-01 | -0.007350 | 9.59e-01 |
| Retrograde neurotrophin signalling | 14 | 9.64e-01 | 0.007020 | 9.79e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 22 | 9.55e-01 | -0.006890 | 9.75e-01 |
| Miscellaneous transport and binding events | 19 | 9.59e-01 | 0.006740 | 9.77e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 9.31e-01 | 0.006730 | 9.62e-01 |
| Cardiac conduction | 70 | 9.28e-01 | 0.006280 | 9.59e-01 |
| Lewis blood group biosynthesis | 10 | 9.74e-01 | -0.006000 | 9.86e-01 |
| Platelet homeostasis | 56 | 9.41e-01 | 0.005680 | 9.70e-01 |
| TNFR2 non-canonical NF-kB pathway | 70 | 9.36e-01 | -0.005540 | 9.66e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 11 | 9.76e-01 | 0.005210 | 9.87e-01 |
| RAB geranylgeranylation | 55 | 9.47e-01 | -0.005170 | 9.72e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 46 | 9.55e-01 | -0.004800 | 9.75e-01 |
| Vif-mediated degradation of APOBEC3G | 46 | 9.56e-01 | 0.004700 | 9.75e-01 |
| TNFs bind their physiological receptors | 10 | 9.80e-01 | 0.004550 | 9.89e-01 |
| Generic Transcription Pathway | 981 | 8.19e-01 | 0.004360 | 8.86e-01 |
| G2/M Transition | 168 | 9.23e-01 | -0.004300 | 9.59e-01 |
| Diseases of metabolism | 177 | 9.24e-01 | -0.004150 | 9.59e-01 |
| Hh mutants abrogate ligand secretion | 51 | 9.61e-01 | -0.003980 | 9.77e-01 |
| Signaling by Hedgehog | 122 | 9.47e-01 | -0.003520 | 9.72e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 61 | 9.66e-01 | 0.003170 | 9.80e-01 |
| Metabolism of vitamins and cofactors | 141 | 9.49e-01 | 0.003130 | 9.73e-01 |
| Hh mutants are degraded by ERAD | 50 | 9.74e-01 | -0.002690 | 9.86e-01 |
| Metabolism of RNA | 650 | 9.08e-01 | -0.002680 | 9.49e-01 |
| Cellular responses to external stimuli | 466 | 9.23e-01 | -0.002620 | 9.59e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 53 | 9.74e-01 | -0.002570 | 9.86e-01 |
| Phase I - Functionalization of compounds | 51 | 9.78e-01 | -0.002280 | 9.87e-01 |
| Cytosolic sulfonation of small molecules | 11 | 9.90e-01 | 0.002100 | 9.94e-01 |
| Neuronal System | 225 | 9.61e-01 | 0.001890 | 9.77e-01 |
| Interaction between L1 and Ankyrins | 18 | 9.90e-01 | -0.001690 | 9.94e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 39 | 9.88e-01 | -0.001420 | 9.94e-01 |
| Amine ligand-binding receptors | 14 | 9.93e-01 | -0.001300 | 9.95e-01 |
| CD28 dependent PI3K/Akt signaling | 16 | 9.94e-01 | -0.001100 | 9.95e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 46 | 9.91e-01 | 0.000996 | 9.94e-01 |
| p53-Independent DNA Damage Response | 46 | 9.91e-01 | 0.000996 | 9.94e-01 |
| p53-Independent G1/S DNA damage checkpoint | 46 | 9.91e-01 | 0.000996 | 9.94e-01 |
| ABC transporter disorders | 60 | 9.90e-01 | -0.000909 | 9.94e-01 |
| Fatty acid metabolism | 116 | 9.90e-01 | 0.000663 | 9.94e-01 |
| RNA Polymerase II Transcription | 1104 | 9.73e-01 | 0.000620 | 9.86e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 54 | 9.96e-01 | 0.000393 | 9.97e-01 |
| Chaperone Mediated Autophagy | 16 | 9.99e-01 | 0.000180 | 9.99e-01 |
Interleukin-35 Signalling
| 522 | |
|---|---|
| set | Interleukin-35 Signalling |
| setSize | 10 |
| pANOVA | 0.000252 |
| s.dist | 0.668 |
| p.adjustANOVA | 0.00328 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| JAK2 | 7829 |
| IL6ST | 7817 |
| STAT3 | 7512 |
| IL27RA | 7071 |
| STAT4 | 5785 |
| JAK1 | 5149 |
| IL12A | 4522 |
| STAT1 | 3403 |
| CANX | 2787 |
| TYK2 | -53 |
| GeneID | Gene Rank |
|---|---|
| JAK2 | 7829 |
| IL6ST | 7817 |
| STAT3 | 7512 |
| IL27RA | 7071 |
| STAT4 | 5785 |
| JAK1 | 5149 |
| IL12A | 4522 |
| STAT1 | 3403 |
| CANX | 2787 |
| TYK2 | -53 |
Peptide chain elongation
| 755 | |
|---|---|
| set | Peptide chain elongation |
| setSize | 85 |
| pANOVA | 1.38e-24 |
| s.dist | 0.642 |
| p.adjustANOVA | 1.79e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| EEF2 | 7264 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| EEF2 | 7264 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| EEF1A1 | 1902 |
| RPS26 | 1750 |
| FAU | 1155 |
| RPSA | -420 |
| RPL26L1 | -949 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| RPL39L | -2911 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
Viral mRNA Translation
| 1253 | |
|---|---|
| set | Viral mRNA Translation |
| setSize | 85 |
| pANOVA | 4.65e-24 |
| s.dist | 0.634 |
| p.adjustANOVA | 1.93e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| DNAJC3 | 5385 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| FAU | 1155 |
| RPSA | -420 |
| RPL26L1 | -949 |
| GRSF1 | -1214 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| RPL39L | -2911 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
Selenocysteine synthesis
| 1000 | |
|---|---|
| set | Selenocysteine synthesis |
| setSize | 88 |
| pANOVA | 3.64e-24 |
| s.dist | 0.625 |
| p.adjustANOVA | 1.93e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| EEFSEC | 4157 |
| RPL18A | 4115 |
| SEPSECS | 4064 |
| RPS12 | 4048 |
| PSTK | 3914 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| FAU | 1155 |
| SEPHS2 | 712 |
| RPSA | -420 |
| SECISBP2 | -656 |
| RPL26L1 | -949 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| RPL39L | -2911 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
Eukaryotic Translation Elongation
| 320 | |
|---|---|
| set | Eukaryotic Translation Elongation |
| setSize | 89 |
| pANOVA | 7.42e-24 |
| s.dist | 0.617 |
| p.adjustANOVA | 1.93e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| EEF2 | 7264 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EEF1B2 | 7240 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| EEF2 | 7264 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EEF1B2 | 7240 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| EEF1A1P5 | 4929 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| EEF1A1 | 1902 |
| RPS26 | 1750 |
| FAU | 1155 |
| RPSA | -420 |
| RPL26L1 | -949 |
| EEF1D | -1847 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| RPL39L | -2911 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EEF1A2 | -8004 |
Eukaryotic Translation Termination
| 322 | |
|---|---|
| set | Eukaryotic Translation Termination |
| setSize | 89 |
| pANOVA | 2.09e-22 |
| s.dist | 0.597 |
| p.adjustANOVA | 3.89e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| GSPT1 | 2038 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| FAU | 1155 |
| APEH | 1035 |
| N6AMT1 | 720 |
| ETF1 | -382 |
| RPSA | -420 |
| RPL26L1 | -949 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| RPL39L | -2911 |
| GSPT2 | -2915 |
| TRMT112 | -3437 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
Selenoamino acid metabolism
| 999 | |
|---|---|
| set | Selenoamino acid metabolism |
| setSize | 101 |
| pANOVA | 6.14e-24 |
| s.dist | 0.581 |
| p.adjustANOVA | 1.93e-21 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NNMT | 7816 |
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| GeneID | Gene Rank |
|---|---|
| NNMT | 7816 |
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| PAPSS2 | 6573 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| SCLY | 6003 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| PAPSS1 | 5772 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| GSR | 4237 |
| EEFSEC | 4157 |
| AIMP1 | 4126 |
| RPL18A | 4115 |
| SEPSECS | 4064 |
| RPS12 | 4048 |
| PSTK | 3914 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| TXNRD1 | 1443 |
| FAU | 1155 |
| SEPHS2 | 712 |
| EEF1E1 | 458 |
| AHCY | -175 |
| RPSA | -420 |
| SECISBP2 | -656 |
| HNMT | -669 |
| RPL26L1 | -949 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| CTH | -2457 |
| AIMP2 | -2901 |
| RPL39L | -2911 |
| CBS | -3626 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
| 948 | |
|---|---|
| set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
| setSize | 97 |
| pANOVA | 9.13e-23 |
| s.dist | 0.577 |
| p.adjustANOVA | 1.98e-20 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| CEBPB | 6860 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| ATF4 | 6010 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| IMPACT | 5444 |
| RPL7A | 5345 |
| EIF2S3 | 5156 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| ATF3 | 3783 |
| EIF2S2 | 3756 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| FAU | 1155 |
| ASNS | 1122 |
| EIF2S1 | 1072 |
| ATF2 | -106 |
| CEBPG | -232 |
| RPSA | -420 |
| DDIT3 | -705 |
| RPL26L1 | -949 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| TRIB3 | -2512 |
| RPL39L | -2911 |
| GCN1 | -4138 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EIF2AK4 | -7460 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
| 695 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
| setSize | 91 |
| pANOVA | 1.49e-20 |
| s.dist | 0.563 |
| p.adjustANOVA | 1.79e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| GSPT1 | 2038 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| FAU | 1155 |
| ETF1 | -382 |
| RPSA | -420 |
| RPL26L1 | -949 |
| NCBP2 | -2083 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| RPL39L | -2911 |
| GSPT2 | -2915 |
| PABPC1 | -3146 |
| NCBP1 | -3996 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| UPF1 | -4980 |
Interleukin-6 signaling
| 526 | |
|---|---|
| set | Interleukin-6 signaling |
| setSize | 11 |
| pANOVA | 0.00128 |
| s.dist | 0.561 |
| p.adjustANOVA | 0.0108 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IL6 | 7832 |
| JAK2 | 7829 |
| IL6ST | 7817 |
| IL6R | 7681 |
| SOCS3 | 7610 |
| STAT3 | 7512 |
| JAK1 | 5149 |
| STAT1 | 3403 |
| PTPN11 | 435 |
| TYK2 | -53 |
| CBL | -7686 |
| GeneID | Gene Rank |
|---|---|
| IL6 | 7832 |
| JAK2 | 7829 |
| IL6ST | 7817 |
| IL6R | 7681 |
| SOCS3 | 7610 |
| STAT3 | 7512 |
| JAK1 | 5149 |
| STAT1 | 3403 |
| PTPN11 | 435 |
| TYK2 | -53 |
| CBL | -7686 |
Formation of a pool of free 40S subunits
| 360 | |
|---|---|
| set | Formation of a pool of free 40S subunits |
| setSize | 97 |
| pANOVA | 1.39e-21 |
| s.dist | 0.56 |
| p.adjustANOVA | 2.27e-19 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| EIF3M | 6006 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| EIF3D | 4212 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| EIF3E | 3912 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| EIF3A | 3092 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| EIF3F | 2186 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| EIF3L | 1225 |
| FAU | 1155 |
| EIF3G | 978 |
| EIF3J | 849 |
| RPSA | -420 |
| EIF3K | -591 |
| EIF3H | -785 |
| RPL26L1 | -949 |
| EIF3B | -1725 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| RPL39L | -2911 |
| EIF3C | -3245 |
| EIF1AX | -4390 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EIF3I | -6241 |
Activation of BAD and translocation to mitochondria
| 31 | |
|---|---|
| set | Activation of BAD and translocation to mitochondria |
| setSize | 12 |
| pANOVA | 0.000812 |
| s.dist | -0.558 |
| p.adjustANOVA | 0.00771 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| YWHAQ | -8005 |
| YWHAZ | -7497 |
| BAD | -7271 |
| YWHAH | -7222 |
| YWHAG | -6528 |
| AKT1 | -5885 |
| YWHAB | -5495 |
| PPP3R1 | -4946 |
| AKT2 | -3273 |
| BID | -1220 |
| PPP3CC | -1068 |
| BCL2 | 3051 |
| GeneID | Gene Rank |
|---|---|
| YWHAQ | -8005 |
| YWHAZ | -7497 |
| BAD | -7271 |
| YWHAH | -7222 |
| YWHAG | -6528 |
| AKT1 | -5885 |
| YWHAB | -5495 |
| PPP3R1 | -4946 |
| AKT2 | -3273 |
| BID | -1220 |
| PPP3CC | -1068 |
| BCL2 | 3051 |
Signaling by Leptin
| 1050 | |
|---|---|
| set | Signaling by Leptin |
| setSize | 10 |
| pANOVA | 0.00269 |
| s.dist | 0.548 |
| p.adjustANOVA | 0.0179 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| JAK2 | 7829 |
| SOCS3 | 7610 |
| STAT3 | 7512 |
| STAT5A | 7092 |
| IRS1 | 6127 |
| LEPR | 4918 |
| IRS2 | 2726 |
| PTPN11 | 435 |
| SH2B1 | -873 |
| STAT5B | -1159 |
| GeneID | Gene Rank |
|---|---|
| JAK2 | 7829 |
| SOCS3 | 7610 |
| STAT3 | 7512 |
| STAT5A | 7092 |
| IRS1 | 6127 |
| LEPR | 4918 |
| IRS2 | 2726 |
| PTPN11 | 435 |
| SH2B1 | -873 |
| STAT5B | -1159 |
Chemokine receptors bind chemokines
| 156 | |
|---|---|
| set | Chemokine receptors bind chemokines |
| setSize | 13 |
| pANOVA | 0.000971 |
| s.dist | 0.528 |
| p.adjustANOVA | 0.00889 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CXCL12 | 7764 |
| CXCL8 | 7701 |
| ACKR3 | 7686 |
| CXCL1 | 7669 |
| CXCL16 | 7218 |
| CXCL3 | 6695 |
| CXCL2 | 6615 |
| CCL2 | 6486 |
| CXCL10 | 5538 |
| CX3CL1 | 2915 |
| CXCL11 | -2762 |
| CCL28 | -4965 |
| CXCR4 | -5734 |
| GeneID | Gene Rank |
|---|---|
| CXCL12 | 7764 |
| CXCL8 | 7701 |
| ACKR3 | 7686 |
| CXCL1 | 7669 |
| CXCL16 | 7218 |
| CXCL3 | 6695 |
| CXCL2 | 6615 |
| CCL2 | 6486 |
| CXCL10 | 5538 |
| CX3CL1 | 2915 |
| CXCL11 | -2762 |
| CCL28 | -4965 |
| CXCR4 | -5734 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF)
| 358 | |
|---|---|
| set | Formation of Senescence-Associated Heterochromatin Foci (SAHF) |
| setSize | 11 |
| pANOVA | 0.00257 |
| s.dist | -0.525 |
| p.adjustANOVA | 0.0177 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -7902 |
| LMNB1 | -7606 |
| HMGA2 | -7482 |
| UBN1 | -6169 |
| HMGA1 | -5337 |
| HIRA | -5319 |
| CABIN1 | -4329 |
| RB1 | -4096 |
| ASF1A | -3941 |
| EP400 | -2000 |
| TP53 | 6352 |
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -7902 |
| LMNB1 | -7606 |
| HMGA2 | -7482 |
| UBN1 | -6169 |
| HMGA1 | -5337 |
| HIRA | -5319 |
| CABIN1 | -4329 |
| RB1 | -4096 |
| ASF1A | -3941 |
| EP400 | -2000 |
| TP53 | 6352 |
L13a-mediated translational silencing of Ceruloplasmin expression
| 546 | |
|---|---|
| set | L13a-mediated translational silencing of Ceruloplasmin expression |
| setSize | 107 |
| pANOVA | 8.22e-21 |
| s.dist | 0.523 |
| p.adjustANOVA | 1.19e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| EIF3M | 6006 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| EIF2S3 | 5156 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| EIF4A1 | 4517 |
| RPS20 | 4323 |
| EIF3D | 4212 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| EIF3E | 3912 |
| RPS5 | 3813 |
| EIF2S2 | 3756 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| EIF3A | 3092 |
| UBA52 | 2829 |
| EIF4B | 2587 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| EIF3F | 2186 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| EIF3L | 1225 |
| FAU | 1155 |
| EIF2S1 | 1072 |
| EIF3G | 978 |
| EIF3J | 849 |
| RPSA | -420 |
| EIF3K | -591 |
| EIF3H | -785 |
| RPL26L1 | -949 |
| EIF3B | -1725 |
| EIF4E | -1791 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| RPL39L | -2911 |
| PABPC1 | -3146 |
| EIF3C | -3245 |
| EIF1AX | -4390 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EIF4H | -5641 |
| EIF3I | -6241 |
RHO GTPases activate KTN1
| 834 | |
|---|---|
| set | RHO GTPases activate KTN1 |
| setSize | 10 |
| pANOVA | 0.00453 |
| s.dist | -0.518 |
| p.adjustANOVA | 0.0253 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAC1 | -7875 |
| RHOA | -7560 |
| CDC42 | -7346 |
| KLC2 | -6543 |
| RHOG | -6426 |
| KIF5B | -6292 |
| KIF5A | -5725 |
| KLC1 | -4607 |
| KLC4 | 2032 |
| KTN1 | 7391 |
| GeneID | Gene Rank |
|---|---|
| RAC1 | -7875 |
| RHOA | -7560 |
| CDC42 | -7346 |
| KLC2 | -6543 |
| RHOG | -6426 |
| KIF5B | -6292 |
| KIF5A | -5725 |
| KLC1 | -4607 |
| KLC4 | 2032 |
| KTN1 | 7391 |
Degradation of cysteine and homocysteine
| 245 | |
|---|---|
| set | Degradation of cysteine and homocysteine |
| setSize | 11 |
| pANOVA | 0.00296 |
| s.dist | -0.517 |
| p.adjustANOVA | 0.0187 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TST | -7965 |
| ADO | -7884 |
| GOT2 | -7808 |
| SLC25A10 | -6670 |
| TXN2 | -5081 |
| ETHE1 | -4561 |
| SUOX | -2761 |
| CTH | -2457 |
| CSAD | -2245 |
| SQRDL | -46 |
| MPST | 318 |
| GeneID | Gene Rank |
|---|---|
| TST | -7965 |
| ADO | -7884 |
| GOT2 | -7808 |
| SLC25A10 | -6670 |
| TXN2 | -5081 |
| ETHE1 | -4561 |
| SUOX | -2761 |
| CTH | -2457 |
| CSAD | -2245 |
| SQRDL | -46 |
| MPST | 318 |
GTP hydrolysis and joining of the 60S ribosomal subunit
| 400 | |
|---|---|
| set | GTP hydrolysis and joining of the 60S ribosomal subunit |
| setSize | 108 |
| pANOVA | 1.51e-20 |
| s.dist | 0.517 |
| p.adjustANOVA | 1.79e-18 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| EIF3M | 6006 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| EIF2S3 | 5156 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| EIF4A1 | 4517 |
| RPS20 | 4323 |
| EIF3D | 4212 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| EIF3E | 3912 |
| RPS5 | 3813 |
| EIF2S2 | 3756 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| EIF3A | 3092 |
| UBA52 | 2829 |
| EIF4B | 2587 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| EIF3F | 2186 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| EIF3L | 1225 |
| FAU | 1155 |
| EIF2S1 | 1072 |
| EIF3G | 978 |
| EIF3J | 849 |
| RPSA | -420 |
| EIF3K | -591 |
| EIF3H | -785 |
| RPL26L1 | -949 |
| EIF3B | -1725 |
| EIF4E | -1791 |
| EIF5B | -1945 |
| RPL36AL | -2092 |
| EIF5 | -2378 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| RPL39L | -2911 |
| EIF3C | -3245 |
| EIF1AX | -4390 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EIF4H | -5641 |
| EIF3I | -6241 |
Synthesis of PIPs at the Golgi membrane
| 1115 | |
|---|---|
| set | Synthesis of PIPs at the Golgi membrane |
| setSize | 15 |
| pANOVA | 0.000586 |
| s.dist | -0.513 |
| p.adjustANOVA | 0.0064 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -7744 |
| PI4K2A | -7435 |
| ARF3 | -7339 |
| SACM1L | -6755 |
| PI4KA | -6411 |
| FIG4 | -6361 |
| OCRL | -6163 |
| VAC14 | -6142 |
| ARF1 | -5829 |
| PI4K2B | -5349 |
| PIK3R4 | -3592 |
| INPP5E | -948 |
| PI4KB | -571 |
| PIK3C3 | 3264 |
| PIK3C2A | 3650 |
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -7744 |
| PI4K2A | -7435 |
| ARF3 | -7339 |
| SACM1L | -6755 |
| PI4KA | -6411 |
| FIG4 | -6361 |
| OCRL | -6163 |
| VAC14 | -6142 |
| ARF1 | -5829 |
| PI4K2B | -5349 |
| PIK3R4 | -3592 |
| INPP5E | -948 |
| PI4KB | -571 |
| PIK3C3 | 3264 |
| PIK3C2A | 3650 |
RHO GTPases activate IQGAPs
| 833 | |
|---|---|
| set | RHO GTPases activate IQGAPs |
| setSize | 10 |
| pANOVA | 0.00531 |
| s.dist | -0.509 |
| p.adjustANOVA | 0.028 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAC1 | -7875 |
| CALM1 | -7505 |
| CDC42 | -7346 |
| CTNNA1 | -7043 |
| IQGAP3 | -5911 |
| IQGAP1 | -4911 |
| CTNNB1 | -4351 |
| MEN1 | -3046 |
| CLIP1 | 954 |
| IQGAP2 | 4826 |
| GeneID | Gene Rank |
|---|---|
| RAC1 | -7875 |
| CALM1 | -7505 |
| CDC42 | -7346 |
| CTNNA1 | -7043 |
| IQGAP3 | -5911 |
| IQGAP1 | -4911 |
| CTNNB1 | -4351 |
| MEN1 | -3046 |
| CLIP1 | 954 |
| IQGAP2 | 4826 |
MAPK3 (ERK1) activation
| 572 | |
|---|---|
| set | MAPK3 (ERK1) activation |
| setSize | 10 |
| pANOVA | 0.00548 |
| s.dist | 0.507 |
| p.adjustANOVA | 0.0286 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IL6 | 7832 |
| JAK2 | 7829 |
| IL6ST | 7817 |
| IL6R | 7681 |
| JAK1 | 5149 |
| MAP2K1 | 3202 |
| CDK1 | 544 |
| PTPN11 | 435 |
| TYK2 | -53 |
| MAPK3 | -1487 |
| GeneID | Gene Rank |
|---|---|
| IL6 | 7832 |
| JAK2 | 7829 |
| IL6ST | 7817 |
| IL6R | 7681 |
| JAK1 | 5149 |
| MAP2K1 | 3202 |
| CDK1 | 544 |
| PTPN11 | 435 |
| TYK2 | -53 |
| MAPK3 | -1487 |
Synthesis of PIPs at the early endosome membrane
| 1116 | |
|---|---|
| set | Synthesis of PIPs at the early endosome membrane |
| setSize | 15 |
| pANOVA | 0.000804 |
| s.dist | -0.5 |
| p.adjustANOVA | 0.00769 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MTMR2 | -8132 |
| INPP4B | -8091 |
| MTMR4 | -8026 |
| MTMR12 | -7782 |
| PIKFYVE | -7744 |
| PI4K2A | -7435 |
| INPP5F | -7392 |
| FIG4 | -6361 |
| VAC14 | -6142 |
| PI4K2B | -5349 |
| PIK3R4 | -3592 |
| MTM1 | 2934 |
| PIK3C3 | 3264 |
| PIK3C2A | 3650 |
| INPP4A | 4012 |
| GeneID | Gene Rank |
|---|---|
| MTMR2 | -8132 |
| INPP4B | -8091 |
| MTMR4 | -8026 |
| MTMR12 | -7782 |
| PIKFYVE | -7744 |
| PI4K2A | -7435 |
| INPP5F | -7392 |
| FIG4 | -6361 |
| VAC14 | -6142 |
| PI4K2B | -5349 |
| PIK3R4 | -3592 |
| MTM1 | 2934 |
| PIK3C3 | 3264 |
| PIK3C2A | 3650 |
| INPP4A | 4012 |
tRNA processing in the mitochondrion
| 1298 | |
|---|---|
| set | tRNA processing in the mitochondrion |
| setSize | 24 |
| pANOVA | 3.01e-05 |
| s.dist | -0.492 |
| p.adjustANOVA | 0.00055 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-ND2 | -8080 |
| MT-CO2 | -7984 |
| MT-ND1 | -7938 |
| MT-CO1 | -7848 |
| MT-ATP6 | -7777 |
| MT-CO3 | -7751 |
| MT-CYB | -7639 |
| MT-ND5 | -7183 |
| MT-ATP8 | -7080 |
| MT-ND3 | -6630 |
| MT-ND4L | -5673 |
| MT-ND4 | -4961 |
| MT-ND6 | -4202 |
| MT-TP | -4196 |
| MT-TW | -3435 |
| MT-TT | -2837 |
| ELAC2 | -2355 |
| MT-RNR2 | -1452 |
| MT-TA | -892 |
| TRMT10C | -756 |
| GeneID | Gene Rank |
|---|---|
| MT-ND2 | -8080 |
| MT-CO2 | -7984 |
| MT-ND1 | -7938 |
| MT-CO1 | -7848 |
| MT-ATP6 | -7777 |
| MT-CO3 | -7751 |
| MT-CYB | -7639 |
| MT-ND5 | -7183 |
| MT-ATP8 | -7080 |
| MT-ND3 | -6630 |
| MT-ND4L | -5673 |
| MT-ND4 | -4961 |
| MT-ND6 | -4202 |
| MT-TP | -4196 |
| MT-TW | -3435 |
| MT-TT | -2837 |
| ELAC2 | -2355 |
| MT-RNR2 | -1452 |
| MT-TA | -892 |
| TRMT10C | -756 |
| MT-RNR1 | -287 |
| HSD17B10 | 142 |
| MT-TI | 1672 |
| TRNT1 | 7180 |
SRP-dependent cotranslational protein targeting to membrane
| 980 | |
|---|---|
| set | SRP-dependent cotranslational protein targeting to membrane |
| setSize | 108 |
| pANOVA | 2.11e-18 |
| s.dist | 0.487 |
| p.adjustANOVA | 2.29e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| SEC11A | 6650 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| SRPRB | 5207 |
| DDOST | 5180 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| SSR1 | 4040 |
| SEC61B | 3969 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| TRAM1 | 3289 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| SSR3 | 2984 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| SPCS3 | 1333 |
| FAU | 1155 |
| SRP19 | 1080 |
| SRP68 | 1063 |
| SEC61A2 | -6 |
| SEC11C | -164 |
| SRP9 | -225 |
| RPSA | -420 |
| RPN2 | -941 |
| RPL26L1 | -949 |
| RPL36AL | -2092 |
| SEC61G | -2298 |
| RPS27L | -2397 |
| SRP72 | -2411 |
| SRP14 | -2710 |
| SPCS2 | -2815 |
| RPL39L | -2911 |
| SRP54 | -3296 |
| SRPRA | -3572 |
| SPCS1 | -4276 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| RPN1 | -5291 |
| SSR2 | -5294 |
| SEC61A1 | -5862 |
| SSR4 | -5869 |
Cap-dependent Translation Initiation
| 127 | |
|---|---|
| set | Cap-dependent Translation Initiation |
| setSize | 115 |
| pANOVA | 2.62e-18 |
| s.dist | 0.471 |
| p.adjustANOVA | 2.44e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| EIF3M | 6006 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| EIF2S3 | 5156 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| EIF2B2 | 4805 |
| RPL35A | 4700 |
| EIF4A1 | 4517 |
| RPS20 | 4323 |
| EIF3D | 4212 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| EIF3E | 3912 |
| RPS5 | 3813 |
| EIF2S2 | 3756 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| EIF3A | 3092 |
| UBA52 | 2829 |
| EIF4B | 2587 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| EIF3F | 2186 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| EIF3L | 1225 |
| FAU | 1155 |
| EIF2S1 | 1072 |
| EIF3G | 978 |
| EIF3J | 849 |
| RPSA | -420 |
| EIF3K | -591 |
| EIF3H | -785 |
| RPL26L1 | -949 |
| EIF2B1 | -1578 |
| EIF2B5 | -1650 |
| EIF3B | -1725 |
| EIF4E | -1791 |
| EIF5B | -1945 |
| RPL36AL | -2092 |
| EIF5 | -2378 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| EIF2B4 | -2683 |
| RPL39L | -2911 |
| PABPC1 | -3146 |
| EIF3C | -3245 |
| EIF2B3 | -3730 |
| EIF1AX | -4390 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EIF4H | -5641 |
| EIF3I | -6241 |
| EIF4EBP1 | -6838 |
Eukaryotic Translation Initiation
| 321 | |
|---|---|
| set | Eukaryotic Translation Initiation |
| setSize | 115 |
| pANOVA | 2.62e-18 |
| s.dist | 0.471 |
| p.adjustANOVA | 2.44e-16 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| EIF4A2 | 7196 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| EIF3M | 6006 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| EIF2S3 | 5156 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| EIF2B2 | 4805 |
| RPL35A | 4700 |
| EIF4A1 | 4517 |
| RPS20 | 4323 |
| EIF3D | 4212 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| EIF3E | 3912 |
| RPS5 | 3813 |
| EIF2S2 | 3756 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| EIF3A | 3092 |
| UBA52 | 2829 |
| EIF4B | 2587 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| EIF3F | 2186 |
| RPS17 | 2073 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| EIF3L | 1225 |
| FAU | 1155 |
| EIF2S1 | 1072 |
| EIF3G | 978 |
| EIF3J | 849 |
| RPSA | -420 |
| EIF3K | -591 |
| EIF3H | -785 |
| RPL26L1 | -949 |
| EIF2B1 | -1578 |
| EIF2B5 | -1650 |
| EIF3B | -1725 |
| EIF4E | -1791 |
| EIF5B | -1945 |
| RPL36AL | -2092 |
| EIF5 | -2378 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| EIF2B4 | -2683 |
| RPL39L | -2911 |
| PABPC1 | -3146 |
| EIF3C | -3245 |
| EIF2B3 | -3730 |
| EIF1AX | -4390 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| EIF4H | -5641 |
| EIF3I | -6241 |
| EIF4EBP1 | -6838 |
Early Phase of HIV Life Cycle
| 306 | |
|---|---|
| set | Early Phase of HIV Life Cycle |
| setSize | 12 |
| pANOVA | 0.00477 |
| s.dist | -0.471 |
| p.adjustANOVA | 0.0262 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KPNA1 | -7954 |
| XRCC5 | -7246 |
| BANF1 | -6818 |
| PPIA | -6813 |
| CXCR4 | -5734 |
| HMGA1 | -5337 |
| FEN1 | -4586 |
| PSIP1 | -2933 |
| LIG1 | -2042 |
| XRCC6 | -1566 |
| LIG4 | 211 |
| XRCC4 | 3865 |
| GeneID | Gene Rank |
|---|---|
| KPNA1 | -7954 |
| XRCC5 | -7246 |
| BANF1 | -6818 |
| PPIA | -6813 |
| CXCR4 | -5734 |
| HMGA1 | -5337 |
| FEN1 | -4586 |
| PSIP1 | -2933 |
| LIG1 | -2042 |
| XRCC6 | -1566 |
| LIG4 | 211 |
| XRCC4 | 3865 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1
| 491 | |
|---|---|
| set | Inhibition of replication initiation of damaged DNA by RB1/E2F1 |
| setSize | 12 |
| pANOVA | 0.00498 |
| s.dist | -0.468 |
| p.adjustANOVA | 0.0268 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| E2F1 | -7730 |
| PRIM2 | -7036 |
| POLA2 | -6956 |
| TFDP2 | -5549 |
| PPP2R1A | -4878 |
| PPP2CB | -4738 |
| PPP2CA | -4611 |
| RB1 | -4096 |
| TFDP1 | -3849 |
| POLA1 | -2924 |
| PRIM1 | -1099 |
| PPP2R1B | 6736 |
| GeneID | Gene Rank |
|---|---|
| E2F1 | -7730 |
| PRIM2 | -7036 |
| POLA2 | -6956 |
| TFDP2 | -5549 |
| PPP2R1A | -4878 |
| PPP2CB | -4738 |
| PPP2CA | -4611 |
| RB1 | -4096 |
| TFDP1 | -3849 |
| POLA1 | -2924 |
| PRIM1 | -1099 |
| PPP2R1B | 6736 |
Interleukin-7 signaling
| 527 | |
|---|---|
| set | Interleukin-7 signaling |
| setSize | 17 |
| pANOVA | 0.000895 |
| s.dist | 0.465 |
| p.adjustANOVA | 0.00843 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| IL7 | 7633 |
| PIK3R1 | 7617 |
| SOCS2 | 7581 |
| STAT3 | 7512 |
| SOCS1 | 7501 |
| STAT5A | 7092 |
| IRS1 | 6127 |
| TSLP | 5482 |
| JAK1 | 5149 |
| PIK3R3 | 3619 |
| IRS2 | 2726 |
| CISH | 1877 |
| BRWD1 | 685 |
| IL7R | -140 |
| STAT5B | -1159 |
| RAG1 | -2134 |
| SMARCA4 | -6668 |
| GeneID | Gene Rank |
|---|---|
| IL7 | 7633 |
| PIK3R1 | 7617 |
| SOCS2 | 7581 |
| STAT3 | 7512 |
| SOCS1 | 7501 |
| STAT5A | 7092 |
| IRS1 | 6127 |
| TSLP | 5482 |
| JAK1 | 5149 |
| PIK3R3 | 3619 |
| IRS2 | 2726 |
| CISH | 1877 |
| BRWD1 | 685 |
| IL7R | -140 |
| STAT5B | -1159 |
| RAG1 | -2134 |
| SMARCA4 | -6668 |
MicroRNA (miRNA) biogenesis
| 611 | |
|---|---|
| set | MicroRNA (miRNA) biogenesis |
| setSize | 23 |
| pANOVA | 0.00012 |
| s.dist | -0.463 |
| p.adjustANOVA | 0.00198 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRKRA | -7621 |
| AGO3 | -7491 |
| POLR2B | -7299 |
| POLR2C | -6952 |
| XPO5 | -6861 |
| AGO2 | -6706 |
| POLR2L | -6552 |
| DICER1 | -6184 |
| POLR2A | -5502 |
| POLR2I | -5220 |
| POLR2J | -4515 |
| POLR2D | -3686 |
| AGO1 | -3601 |
| DROSHA | -3282 |
| DGCR8 | -3176 |
| BCDIN3D | -3063 |
| POLR2E | -2326 |
| POLR2H | -2271 |
| TARBP2 | -2252 |
| RAN | -2132 |
| GeneID | Gene Rank |
|---|---|
| PRKRA | -7621 |
| AGO3 | -7491 |
| POLR2B | -7299 |
| POLR2C | -6952 |
| XPO5 | -6861 |
| AGO2 | -6706 |
| POLR2L | -6552 |
| DICER1 | -6184 |
| POLR2A | -5502 |
| POLR2I | -5220 |
| POLR2J | -4515 |
| POLR2D | -3686 |
| AGO1 | -3601 |
| DROSHA | -3282 |
| DGCR8 | -3176 |
| BCDIN3D | -3063 |
| POLR2E | -2326 |
| POLR2H | -2271 |
| TARBP2 | -2252 |
| RAN | -2132 |
| AGO4 | 410 |
| POLR2K | 1794 |
| POLR2G | 5897 |
G beta:gamma signalling through CDC42
| 375 | |
|---|---|
| set | G beta:gamma signalling through CDC42 |
| setSize | 13 |
| pANOVA | 0.00423 |
| s.dist | -0.458 |
| p.adjustANOVA | 0.0244 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| ARHGEF6 | -7731 |
| CDC42 | -7346 |
| GNG2 | -6182 |
| PAK1 | -5068 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| ARHGEF6 | -7731 |
| CDC42 | -7346 |
| GNG2 | -6182 |
| PAK1 | -5068 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
G-protein beta:gamma signalling
| 380 | |
|---|---|
| set | G-protein beta:gamma signalling |
| setSize | 20 |
| pANOVA | 0.000405 |
| s.dist | -0.457 |
| p.adjustANOVA | 0.00496 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIK3CG | -8121 |
| GNB1 | -7832 |
| ARHGEF6 | -7731 |
| RHOA | -7560 |
| CDC42 | -7346 |
| GNG2 | -6182 |
| AKT1 | -5885 |
| PAK1 | -5068 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| AKT2 | -3273 |
| PDPK1 | -1474 |
| PLCB2 | -254 |
| PLCB3 | 119 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
| GeneID | Gene Rank |
|---|---|
| PIK3CG | -8121 |
| GNB1 | -7832 |
| ARHGEF6 | -7731 |
| RHOA | -7560 |
| CDC42 | -7346 |
| GNG2 | -6182 |
| AKT1 | -5885 |
| PAK1 | -5068 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| AKT2 | -3273 |
| PDPK1 | -1474 |
| PLCB2 | -254 |
| PLCB3 | 119 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
Listeria monocytogenes entry into host cells
| 558 | |
|---|---|
| set | Listeria monocytogenes entry into host cells |
| setSize | 19 |
| pANOVA | 0.000652 |
| s.dist | -0.452 |
| p.adjustANOVA | 0.00683 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MET | -7772 |
| SRC | -7694 |
| CBL | -7686 |
| UBC | -7510 |
| STAM | -7142 |
| SH3KBP1 | -6821 |
| HGS | -6028 |
| SH3GL3 | -5152 |
| GRB2 | -5151 |
| SH3GL1 | -5098 |
| CTNND1 | -4669 |
| CTNNB1 | -4351 |
| STAM2 | -4166 |
| CBLL1 | -2513 |
| EPS15 | -775 |
| SH3GL2 | 1067 |
| UBB | 2232 |
| UBA52 | 2829 |
| RPS27A | 4934 |
| GeneID | Gene Rank |
|---|---|
| MET | -7772 |
| SRC | -7694 |
| CBL | -7686 |
| UBC | -7510 |
| STAM | -7142 |
| SH3KBP1 | -6821 |
| HGS | -6028 |
| SH3GL3 | -5152 |
| GRB2 | -5151 |
| SH3GL1 | -5098 |
| CTNND1 | -4669 |
| CTNNB1 | -4351 |
| STAM2 | -4166 |
| CBLL1 | -2513 |
| EPS15 | -775 |
| SH3GL2 | 1067 |
| UBB | 2232 |
| UBA52 | 2829 |
| RPS27A | 4934 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
| 923 | |
|---|---|
| set | Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells |
| setSize | 13 |
| pANOVA | 0.00484 |
| s.dist | -0.451 |
| p.adjustANOVA | 0.0263 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RBPJ | -7836 |
| MAML3 | -7770 |
| ONECUT3 | -6500 |
| KAT2B | -5524 |
| MAMLD1 | -4145 |
| EP300 | -4071 |
| MAML1 | -3725 |
| MAML2 | -3503 |
| NOTCH1 | -3443 |
| SNW1 | -3026 |
| CREBBP | -1636 |
| KAT2A | -1025 |
| HES1 | 3338 |
| GeneID | Gene Rank |
|---|---|
| RBPJ | -7836 |
| MAML3 | -7770 |
| ONECUT3 | -6500 |
| KAT2B | -5524 |
| MAMLD1 | -4145 |
| EP300 | -4071 |
| MAML1 | -3725 |
| MAML2 | -3503 |
| NOTCH1 | -3443 |
| SNW1 | -3026 |
| CREBBP | -1636 |
| KAT2A | -1025 |
| HES1 | 3338 |
G beta:gamma signalling through PI3Kgamma
| 376 | |
|---|---|
| set | G beta:gamma signalling through PI3Kgamma |
| setSize | 15 |
| pANOVA | 0.00278 |
| s.dist | -0.446 |
| p.adjustANOVA | 0.0179 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIK3CG | -8121 |
| GNB1 | -7832 |
| RHOA | -7560 |
| GNG2 | -6182 |
| AKT1 | -5885 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| AKT2 | -3273 |
| PDPK1 | -1474 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
| GeneID | Gene Rank |
|---|---|
| PIK3CG | -8121 |
| GNB1 | -7832 |
| RHOA | -7560 |
| GNG2 | -6182 |
| AKT1 | -5885 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| AKT2 | -3273 |
| PDPK1 | -1474 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
CRMPs in Sema3A signaling
| 119 | |
|---|---|
| set | CRMPs in Sema3A signaling |
| setSize | 14 |
| pANOVA | 0.00387 |
| s.dist | -0.446 |
| p.adjustANOVA | 0.0232 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GSK3B | -7750 |
| PLXNA2 | -7469 |
| DPYSL5 | -6593 |
| NRP1 | -6126 |
| SEMA3A | -5796 |
| PLXNA3 | -5021 |
| CDK5R1 | -4814 |
| DPYSL3 | -4087 |
| CDK5 | -1831 |
| DPYSL4 | -1491 |
| FYN | -928 |
| PLXNA4 | -751 |
| DPYSL2 | 176 |
| PLXNA1 | 461 |
| GeneID | Gene Rank |
|---|---|
| GSK3B | -7750 |
| PLXNA2 | -7469 |
| DPYSL5 | -6593 |
| NRP1 | -6126 |
| SEMA3A | -5796 |
| PLXNA3 | -5021 |
| CDK5R1 | -4814 |
| DPYSL3 | -4087 |
| CDK5 | -1831 |
| DPYSL4 | -1491 |
| FYN | -928 |
| PLXNA4 | -751 |
| DPYSL2 | 176 |
| PLXNA1 | 461 |
Post-chaperonin tubulin folding pathway
| 782 | |
|---|---|
| set | Post-chaperonin tubulin folding pathway |
| setSize | 15 |
| pANOVA | 0.00294 |
| s.dist | -0.444 |
| p.adjustANOVA | 0.0186 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TUBB6 | -7684 |
| TUBA1B | -7630 |
| TUBB4B | -7275 |
| TUBA1A | -7206 |
| TUBA1C | -6246 |
| ARL2 | -5839 |
| TUBA4A | -5753 |
| TUBB3 | -3595 |
| TUBB2A | -3212 |
| TBCC | -3148 |
| TBCD | -2492 |
| TUBB2B | -1552 |
| TBCE | 1383 |
| TBCA | 1475 |
| TBCB | 3327 |
| GeneID | Gene Rank |
|---|---|
| TUBB6 | -7684 |
| TUBA1B | -7630 |
| TUBB4B | -7275 |
| TUBA1A | -7206 |
| TUBA1C | -6246 |
| ARL2 | -5839 |
| TUBA4A | -5753 |
| TUBB3 | -3595 |
| TUBB2A | -3212 |
| TBCC | -3148 |
| TBCD | -2492 |
| TUBB2B | -1552 |
| TBCE | 1383 |
| TBCA | 1475 |
| TBCB | 3327 |
Growth hormone receptor signaling
| 436 | |
|---|---|
| set | Growth hormone receptor signaling |
| setSize | 19 |
| pANOVA | 0.000989 |
| s.dist | 0.436 |
| p.adjustANOVA | 0.00897 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| JAK2 | 7829 |
| SOCS3 | 7610 |
| SOCS2 | 7581 |
| STAT3 | 7512 |
| SOCS1 | 7501 |
| PRLR | 7396 |
| STAT5A | 7092 |
| GHR | 6518 |
| IRS1 | 6127 |
| ADAM17 | 5433 |
| STAT1 | 3403 |
| LYN | 3308 |
| IRS2 | 2726 |
| CISH | 1877 |
| SH2B1 | -873 |
| STAT5B | -1159 |
| MAPK3 | -1487 |
| PTPN1 | -7258 |
| MAPK1 | -7898 |
| GeneID | Gene Rank |
|---|---|
| JAK2 | 7829 |
| SOCS3 | 7610 |
| SOCS2 | 7581 |
| STAT3 | 7512 |
| SOCS1 | 7501 |
| PRLR | 7396 |
| STAT5A | 7092 |
| GHR | 6518 |
| IRS1 | 6127 |
| ADAM17 | 5433 |
| STAT1 | 3403 |
| LYN | 3308 |
| IRS2 | 2726 |
| CISH | 1877 |
| SH2B1 | -873 |
| STAT5B | -1159 |
| MAPK3 | -1487 |
| PTPN1 | -7258 |
| MAPK1 | -7898 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
| 694 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
| setSize | 111 |
| pANOVA | 2.87e-15 |
| s.dist | 0.434 |
| p.adjustANOVA | 2.33e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| UPF3B | 6030 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| MAGOH | 4551 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UPF3A | 3001 |
| UPF2 | 2989 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| GSPT1 | 2038 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| PNRC2 | 1666 |
| FAU | 1155 |
| EIF4A3 | 1055 |
| RBM8A | 619 |
| SMG8 | 191 |
| ETF1 | -382 |
| RPSA | -420 |
| RNPS1 | -731 |
| RPL26L1 | -949 |
| MAGOHB | -1455 |
| SMG5 | -1693 |
| NCBP2 | -2083 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| RPL39L | -2911 |
| GSPT2 | -2915 |
| PABPC1 | -3146 |
| SMG1 | -3382 |
| SMG9 | -3764 |
| NCBP1 | -3996 |
| PPP2CA | -4611 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| PPP2R1A | -4878 |
| UPF1 | -4980 |
| SMG6 | -5010 |
| CASC3 | -5018 |
| PPP2R2A | -5145 |
| DCP1A | -5628 |
| SMG7 | -7083 |
Nonsense-Mediated Decay (NMD)
| 696 | |
|---|---|
| set | Nonsense-Mediated Decay (NMD) |
| setSize | 111 |
| pANOVA | 2.87e-15 |
| s.dist | 0.434 |
| p.adjustANOVA | 2.33e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| GeneID | Gene Rank |
|---|---|
| RPS3 | 7709 |
| RPL36A | 7564 |
| RPL5 | 7546 |
| RPS4X | 7545 |
| RPL11 | 7506 |
| RPL35 | 7491 |
| RPL13 | 7482 |
| RPL37A | 7469 |
| RPL12 | 7451 |
| RPS8 | 7346 |
| RPL37 | 7299 |
| RPL21 | 7288 |
| RPL10A | 7263 |
| RPL8 | 7250 |
| RPS6 | 7142 |
| RPL3 | 7084 |
| RPL41 | 7005 |
| RPL7 | 6994 |
| RPL13A | 6981 |
| RPS10 | 6958 |
| RPL23 | 6955 |
| RPL27 | 6873 |
| RPS7 | 6848 |
| RPL6 | 6714 |
| RPL15 | 6711 |
| RPL18 | 6682 |
| RPL26 | 6620 |
| RPL31 | 6576 |
| RPS24 | 6550 |
| RPL22 | 6484 |
| RPL23A | 6456 |
| RPL19 | 6446 |
| RPS14 | 6423 |
| RPL34 | 6142 |
| RPL38 | 6116 |
| RPL36 | 6094 |
| UPF3B | 6030 |
| RPS11 | 5993 |
| RPS15 | 5978 |
| RPL32 | 5962 |
| RPL27A | 5942 |
| RPS21 | 5904 |
| RPS16 | 5868 |
| RPLP1 | 5853 |
| RPS3A | 5838 |
| RPS25 | 5817 |
| RPL29 | 5699 |
| RPS15A | 5641 |
| RPL10 | 5601 |
| RPL17 | 5565 |
| RPL4 | 5548 |
| RPL30 | 5499 |
| RPL9 | 5491 |
| RPL7A | 5345 |
| RPL28 | 5153 |
| RPL24 | 5002 |
| RPS19 | 4957 |
| RPS27A | 4934 |
| RPS23 | 4925 |
| RPL39 | 4832 |
| RPL35A | 4700 |
| MAGOH | 4551 |
| RPS20 | 4323 |
| RPL18A | 4115 |
| RPS12 | 4048 |
| RPS5 | 3813 |
| RPS2 | 3733 |
| RPS27 | 3395 |
| RPS9 | 3266 |
| RPS13 | 3116 |
| UPF3A | 3001 |
| UPF2 | 2989 |
| UBA52 | 2829 |
| RPS29 | 2299 |
| RPLP0 | 2239 |
| RPL14 | 2227 |
| RPS17 | 2073 |
| GSPT1 | 2038 |
| RPL22L1 | 1964 |
| RPS26 | 1750 |
| PNRC2 | 1666 |
| FAU | 1155 |
| EIF4A3 | 1055 |
| RBM8A | 619 |
| SMG8 | 191 |
| ETF1 | -382 |
| RPSA | -420 |
| RNPS1 | -731 |
| RPL26L1 | -949 |
| MAGOHB | -1455 |
| SMG5 | -1693 |
| NCBP2 | -2083 |
| RPL36AL | -2092 |
| RPS27L | -2397 |
| EIF4G1 | -2493 |
| RPL39L | -2911 |
| GSPT2 | -2915 |
| PABPC1 | -3146 |
| SMG1 | -3382 |
| SMG9 | -3764 |
| NCBP1 | -3996 |
| PPP2CA | -4611 |
| RPS28 | -4755 |
| RPLP2 | -4796 |
| PPP2R1A | -4878 |
| UPF1 | -4980 |
| SMG6 | -5010 |
| CASC3 | -5018 |
| PPP2R2A | -5145 |
| DCP1A | -5628 |
| SMG7 | -7083 |
Activation of G protein gated Potassium channels
| 33 | |
|---|---|
| set | Activation of G protein gated Potassium channels |
| setSize | 13 |
| pANOVA | 0.00678 |
| s.dist | -0.434 |
| p.adjustANOVA | 0.0327 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| KCNJ12 | -6805 |
| GNG2 | -6182 |
| GABBR2 | -5685 |
| KCNJ2 | -5104 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| KCNJ12 | -6805 |
| GNG2 | -6182 |
| GABBR2 | -5685 |
| KCNJ2 | -5104 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
G protein gated Potassium channels
| 378 | |
|---|---|
| set | G protein gated Potassium channels |
| setSize | 13 |
| pANOVA | 0.00678 |
| s.dist | -0.434 |
| p.adjustANOVA | 0.0327 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| KCNJ12 | -6805 |
| GNG2 | -6182 |
| GABBR2 | -5685 |
| KCNJ2 | -5104 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| KCNJ12 | -6805 |
| GNG2 | -6182 |
| GABBR2 | -5685 |
| KCNJ2 | -5104 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
| 489 | |
|---|---|
| set | Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits |
| setSize | 13 |
| pANOVA | 0.00678 |
| s.dist | -0.434 |
| p.adjustANOVA | 0.0327 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| KCNJ12 | -6805 |
| GNG2 | -6182 |
| GABBR2 | -5685 |
| KCNJ2 | -5104 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
| GeneID | Gene Rank |
|---|---|
| GNB1 | -7832 |
| KCNJ12 | -6805 |
| GNG2 | -6182 |
| GABBR2 | -5685 |
| KCNJ2 | -5104 |
| GNG5 | -4990 |
| GNG11 | -4466 |
| GNB5 | -3927 |
| GNG12 | -3607 |
| GNB3 | -3342 |
| GNB2 | 190 |
| GNG4 | 2080 |
| GNB4 | 2633 |
Regulation of IFNA signaling
| 897 | |
|---|---|
| set | Regulation of IFNA signaling |
| setSize | 11 |
| pANOVA | 0.0131 |
| s.dist | 0.432 |
| p.adjustANOVA | 0.0531 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SOCS3 | 7610 |
| IFNAR2 | 7587 |
| SOCS1 | 7501 |
| JAK1 | 5149 |
| USP18 | 4998 |
| IFNAR1 | 4326 |
| STAT1 | 3403 |
| STAT2 | 2532 |
| PTPN11 | 435 |
| TYK2 | -53 |
| PTPN1 | -7258 |
| GeneID | Gene Rank |
|---|---|
| SOCS3 | 7610 |
| IFNAR2 | 7587 |
| SOCS1 | 7501 |
| JAK1 | 5149 |
| USP18 | 4998 |
| IFNAR1 | 4326 |
| STAT1 | 3403 |
| STAT2 | 2532 |
| PTPN11 | 435 |
| TYK2 | -53 |
| PTPN1 | -7258 |
Notch-HLH transcription pathway
| 698 | |
|---|---|
| set | Notch-HLH transcription pathway |
| setSize | 25 |
| pANOVA | 0.000212 |
| s.dist | -0.428 |
| p.adjustANOVA | 0.00293 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RBPJ | -7836 |
| MAML3 | -7770 |
| HDAC8 | -7426 |
| HDAC1 | -7409 |
| HDAC5 | -6907 |
| HDAC7 | -6800 |
| NOTCH2 | -6323 |
| HDAC9 | -6283 |
| HDAC2 | -6053 |
| HDAC6 | -5702 |
| KAT2B | -5524 |
| HDAC3 | -5428 |
| NCOR2 | -4774 |
| MAMLD1 | -4145 |
| MAML1 | -3725 |
| MAML2 | -3503 |
| NOTCH1 | -3443 |
| SNW1 | -3026 |
| NCOR1 | -2380 |
| CREBBP | -1636 |
| GeneID | Gene Rank |
|---|---|
| RBPJ | -7836 |
| MAML3 | -7770 |
| HDAC8 | -7426 |
| HDAC1 | -7409 |
| HDAC5 | -6907 |
| HDAC7 | -6800 |
| NOTCH2 | -6323 |
| HDAC9 | -6283 |
| HDAC2 | -6053 |
| HDAC6 | -5702 |
| KAT2B | -5524 |
| HDAC3 | -5428 |
| NCOR2 | -4774 |
| MAMLD1 | -4145 |
| MAML1 | -3725 |
| MAML2 | -3503 |
| NOTCH1 | -3443 |
| SNW1 | -3026 |
| NCOR1 | -2380 |
| CREBBP | -1636 |
| KAT2A | -1025 |
| TBL1X | 3314 |
| HDAC11 | 3495 |
| TBL1XR1 | 4631 |
| HDAC4 | 6421 |
Establishment of Sister Chromatid Cohesion
| 317 | |
|---|---|
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 11 |
| pANOVA | 0.0142 |
| s.dist | -0.427 |
| p.adjustANOVA | 0.0556 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ESCO1 | -7099 |
| STAG2 | -6231 |
| CDCA5 | -6025 |
| WAPL | -5377 |
| RAD21 | -4630 |
| STAG1 | -3389 |
| PDS5A | -2850 |
| SMC3 | -2842 |
| SMC1A | -1818 |
| ESCO2 | -480 |
| PDS5B | 1524 |
| GeneID | Gene Rank |
|---|---|
| ESCO1 | -7099 |
| STAG2 | -6231 |
| CDCA5 | -6025 |
| WAPL | -5377 |
| RAD21 | -4630 |
| STAG1 | -3389 |
| PDS5A | -2850 |
| SMC3 | -2842 |
| SMC1A | -1818 |
| ESCO2 | -480 |
| PDS5B | 1524 |
Gluconeogenesis
| 417 | |
|---|---|
| set | Gluconeogenesis |
| setSize | 25 |
| pANOVA | 0.000233 |
| s.dist | -0.425 |
| p.adjustANOVA | 0.00319 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC37A2 | -8071 |
| GOT2 | -7808 |
| ENO2 | -6707 |
| SLC25A10 | -6670 |
| PC | -6582 |
| SLC25A13 | -6521 |
| SLC37A4 | -6501 |
| MDH2 | -6461 |
| G6PC3 | -6380 |
| SLC25A11 | -6368 |
| PGAM1 | -6092 |
| GOT1 | -5415 |
| SLC25A1 | -5135 |
| GAPDH | -4566 |
| GPI | -3774 |
| PCK2 | -2249 |
| TPI1 | -1874 |
| SLC25A12 | -1695 |
| ENO3 | -636 |
| ALDOA | -80 |
| GeneID | Gene Rank |
|---|---|
| SLC37A2 | -8071 |
| GOT2 | -7808 |
| ENO2 | -6707 |
| SLC25A10 | -6670 |
| PC | -6582 |
| SLC25A13 | -6521 |
| SLC37A4 | -6501 |
| MDH2 | -6461 |
| G6PC3 | -6380 |
| SLC25A11 | -6368 |
| PGAM1 | -6092 |
| GOT1 | -5415 |
| SLC25A1 | -5135 |
| GAPDH | -4566 |
| GPI | -3774 |
| PCK2 | -2249 |
| TPI1 | -1874 |
| SLC25A12 | -1695 |
| ENO3 | -636 |
| ALDOA | -80 |
| ALDOC | 49 |
| MDH1 | 635 |
| ENO1 | 1892 |
| PGK1 | 2282 |
| SLC37A1 | 6027 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes
| 1120 | |
|---|---|
| set | Synthesis of active ubiquitin: roles of E1 and E2 enzymes |
| setSize | 30 |
| pANOVA | 5.71e-05 |
| s.dist | -0.425 |
| p.adjustANOVA | 0.00102 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBE2A | -8137 |
| UBE2D1 | -8102 |
| UBE2G1 | -7862 |
| OTULIN | -7633 |
| UBC | -7510 |
| UBE2Z | -7449 |
| UBE2R2 | -7310 |
| UBE2E3 | -7018 |
| UBE2E1 | -6943 |
| UCHL3 | -6826 |
| UBE2D2 | -6675 |
| UBA1 | -6440 |
| UBE2K | -6204 |
| USP9X | -6141 |
| UBE2S | -5666 |
| USP5 | -5395 |
| UBE2C | -5051 |
| UBE2B | -4444 |
| CDC34 | -4394 |
| UBE2Q2 | -3054 |
| GeneID | Gene Rank |
|---|---|
| UBE2A | -8137 |
| UBE2D1 | -8102 |
| UBE2G1 | -7862 |
| OTULIN | -7633 |
| UBC | -7510 |
| UBE2Z | -7449 |
| UBE2R2 | -7310 |
| UBE2E3 | -7018 |
| UBE2E1 | -6943 |
| UCHL3 | -6826 |
| UBE2D2 | -6675 |
| UBA1 | -6440 |
| UBE2K | -6204 |
| USP9X | -6141 |
| UBE2S | -5666 |
| USP5 | -5395 |
| UBE2C | -5051 |
| UBE2B | -4444 |
| CDC34 | -4394 |
| UBE2Q2 | -3054 |
| UBE2W | -2430 |
| UBE2L3 | -1481 |
| USP7 | 540 |
| UBE2H | 2039 |
| UBB | 2232 |
| UBE2T | 2461 |
| UBA52 | 2829 |
| RPS27A | 4934 |
| UBA6 | 4968 |
| UBE2G2 | 5910 |
Suppression of phagosomal maturation
| 1103 | |
|---|---|
| set | Suppression of phagosomal maturation |
| setSize | 12 |
| pANOVA | 0.0121 |
| s.dist | -0.418 |
| p.adjustANOVA | 0.0513 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAB5A | -8050 |
| KPNA1 | -7954 |
| UBC | -7510 |
| RAB7A | -6858 |
| HGS | -6028 |
| KPNB1 | -5789 |
| CORO1A | -4642 |
| ATP6V1H | -2658 |
| VPS33B | -2436 |
| UBB | 2232 |
| UBA52 | 2829 |
| RPS27A | 4934 |
| GeneID | Gene Rank |
|---|---|
| RAB5A | -8050 |
| KPNA1 | -7954 |
| UBC | -7510 |
| RAB7A | -6858 |
| HGS | -6028 |
| KPNB1 | -5789 |
| CORO1A | -4642 |
| ATP6V1H | -2658 |
| VPS33B | -2436 |
| UBB | 2232 |
| UBA52 | 2829 |
| RPS27A | 4934 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.0.3 (2020-10-10)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.2 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.1.0 GGally_2.0.0
## [3] reshape2_1.4.4 beeswarm_0.2.3
## [5] gtools_3.8.2 echarts4r_0.3.3
## [7] vioplot_0.3.5 zoo_1.8-8
## [9] sm_2.2-5.6 mitch_1.2.2
## [11] gplots_3.1.0 fgsea_1.16.0
## [13] DESeq2_1.30.0 SummarizedExperiment_1.20.0
## [15] Biobase_2.50.0 MatrixGenerics_1.2.0
## [17] matrixStats_0.57.0 GenomicRanges_1.42.0
## [19] GenomeInfoDb_1.26.0 IRanges_2.24.0
## [21] S4Vectors_0.28.0 BiocGenerics_0.36.0
## [23] forcats_0.5.0 stringr_1.4.0
## [25] dplyr_1.0.2 purrr_0.3.4
## [27] readr_1.4.0 tidyr_1.1.2
## [29] tibble_3.0.4 ggplot2_3.3.2
## [31] tidyverse_1.3.0
##
## loaded via a namespace (and not attached):
## [1] colorspace_2.0-0 ellipsis_0.3.1 rprojroot_1.3-2
## [4] XVector_0.30.0 fs_1.5.0 rstudioapi_0.12
## [7] bit64_4.0.5 AnnotationDbi_1.52.0 fansi_0.4.1
## [10] lubridate_1.7.9 xml2_1.3.2 splines_4.0.3
## [13] geneplotter_1.68.0 knitr_1.30 jsonlite_1.7.1
## [16] broom_0.7.2 annotate_1.68.0 dbplyr_2.0.0
## [19] shiny_1.5.0 compiler_4.0.3 httr_1.4.2
## [22] backports_1.2.0 assertthat_0.2.1 Matrix_1.2-18
## [25] fastmap_1.0.1 cli_2.1.0 later_1.1.0.1
## [28] htmltools_0.5.0 tools_4.0.3 gtable_0.3.0
## [31] glue_1.4.2 GenomeInfoDbData_1.2.4 fastmatch_1.1-0
## [34] Rcpp_1.0.5 cellranger_1.1.0 vctrs_0.3.4
## [37] xfun_0.19 ps_1.4.0 testthat_3.0.0
## [40] rvest_0.3.6 mime_0.9 lifecycle_0.2.0
## [43] XML_3.99-0.5 zlibbioc_1.36.0 MASS_7.3-53
## [46] scales_1.1.1 hms_0.5.3 promises_1.1.1
## [49] RColorBrewer_1.1-2 yaml_2.2.1 memoise_1.1.0
## [52] gridExtra_2.3 reshape_0.8.8 stringi_1.5.3
## [55] RSQLite_2.2.1 highr_0.8 genefilter_1.72.0
## [58] desc_1.2.0 caTools_1.18.0 BiocParallel_1.24.1
## [61] rlang_0.4.8 pkgconfig_2.0.3 bitops_1.0-6
## [64] evaluate_0.14 lattice_0.20-41 htmlwidgets_1.5.2
## [67] bit_4.0.4 tidyselect_1.1.0 plyr_1.8.6
## [70] magrittr_1.5 R6_2.5.0 generics_0.1.0
## [73] DelayedArray_0.16.0 DBI_1.1.0 pillar_1.4.6
## [76] haven_2.3.1 withr_2.3.0 survival_3.2-7
## [79] RCurl_1.98-1.2 modelr_0.1.8 crayon_1.3.4
## [82] KernSmooth_2.23-18 rmarkdown_2.5 locfit_1.5-9.4
## [85] grid_4.0.3 readxl_1.3.1 data.table_1.13.2
## [88] blob_1.2.1 reprex_0.3.0 digest_0.6.27
## [91] xtable_1.8-4 httpuv_1.5.4 munsell_0.5.0
## [94] tcltk_4.0.3
END of report